Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3908 |
Name | lung non-small cell carcinoma |
Definition | A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA act mut | Pictilisib | lung non-small cell carcinoma | sensitive | detail... |
PTEN del | PF-04691502 | lung non-small cell carcinoma | predicted - sensitive | detail... |
PTEN loss | Pictilisib | lung non-small cell carcinoma | sensitive | detail... |
BRAF Y472C | Dasatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | Dasatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib | lung non-small cell carcinoma | sensitive | detail... |
TP53 P72R | Cisplatin + Irinotecan | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK S1206Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
PIK3CA E545K | Copanlisib + Paclitaxel | lung non-small cell carcinoma | sensitive | detail... |
RET act mut | Ponatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK positive | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK G1269A | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ensartinib + Sirolimus | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK V1180L | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA mutant | PWT33597 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A loss | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Ceritinib | lung non-small cell carcinoma | conflicting | detail... |
NRAS Q61K | Gedatolisib | lung non-small cell carcinoma | decreased response | detail... |
TP53 R158G | Gedatolisib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171T | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ceritinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK mut | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK V1180L | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK V1180L | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | TAE226 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Zoligratinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 R248W | APR-246 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
TP53 R273H | APR-246 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Navitoclax + Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Navitoclax + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | Trametinib + TW-37 | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | TW-37 + Vemurafenib | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | CEP-8983 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
TP53 mutant | CEP-8983 + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | LY3009120 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Dabrafenib | lung non-small cell carcinoma | resistant | detail... |
ROS1 rearrange | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ATM loss | Ceralasertib + Cisplatin | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Luminespib | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK G1202R | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Fexagratinib | lung non-small cell carcinoma | sensitive | detail... |
RET fusion | Vandetanib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange ALK neg | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK mutant | Crizotinib + Onalespib | lung non-small cell carcinoma | no benefit | detail... |
BRAF L485Y | GDC0879 | lung non-small cell carcinoma | resistant | detail... |
BRAF wild-type | GDC0879 | lung non-small cell carcinoma | resistant | detail... |
BRAF L597V NRAS Q61K | AZ628 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | TAK-632 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | TAK-632 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | PLX7904 | lung non-small cell carcinoma | decreased response | detail... |
BRAF L597V NRAS Q61K | Vemurafenib | lung non-small cell carcinoma | decreased response | detail... |
BRAF G466V | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF L597V NRAS Q61K | Dabrafenib | lung non-small cell carcinoma | decreased response | detail... |
TP53 wild-type | KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | Cisplatin + KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
TP53 wild-type | Carboplatin + KRT-232 | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Everolimus + Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib + Sorafenib | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Pimasertib + Regorafenib | lung non-small cell carcinoma | sensitive | detail... |
CHEK1 positive | Prexasertib | lung non-small cell carcinoma | predicted - sensitive | detail... |
PIK3CA mutant | PF-04691502 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
FGFR2 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
FGFR3 amp | PRN1371 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Nivolumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Pembrolizumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Durvalumab | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Atezolizumab | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO4987655 | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | RO5126766 | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 amp | Selumetinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange ALK E1210K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange MAP2K1 K57N | Ceritinib + Selumetinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA G118D | LY3023414 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Afatinib + Alectinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | E7090 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | NGI-1 | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Brigatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF mutant | Dabrafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469V | Sorafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | Vemurafenib | lung non-small cell carcinoma | resistant | detail... |
BRAF G469A | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Trametinib + Vemurafenib | lung non-small cell carcinoma | conflicting | detail... |
ROS1 rearrange | NPS-1034 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
SMARCA4 mutant | Tozasertib | lung non-small cell carcinoma | predicted - sensitive | detail... |
SMARCA4 loss | Tozasertib | lung non-small cell carcinoma | sensitive | detail... |
ALK positive | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Alectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK I1171N | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1202R | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK F1245C | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1245C | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
SMARCA4 inact mut | Tozasertib | lung non-small cell carcinoma | sensitive | detail... |
SMARCA4 inact mut | Alisertib | lung non-small cell carcinoma | sensitive | detail... |
SMARCA4 inact mut | Danusertib | lung non-small cell carcinoma | sensitive | detail... |
SMARCA4 inact mut | MK-5108 | lung non-small cell carcinoma | sensitive | detail... |
SMARCA4 inact mut | ENMD-2076 | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Cabozantinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Vandetanib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Sunitinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET rearrange | RXDX-105 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 mutant | Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA H1047X | Taselisib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | GSK3052230 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V NRAS Q61K | Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF mutant | KO-947 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466V | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
TP53 negative | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 R175H | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 S215G | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 Y220C | Seliciclib | lung non-small cell carcinoma | resistant | detail... |
TP53 P98A | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 A159V | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 Y234C | Seliciclib | lung non-small cell carcinoma | decreased response | detail... |
TP53 wild-type | Seliciclib | lung non-small cell carcinoma | sensitive | detail... |
NRAS mutant | KO-947 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp NRAS amp | Infigratinib | lung non-small cell carcinoma | resistant | detail... |
FGFR1 amp NRAS amp | Trametinib | lung non-small cell carcinoma | resistant | detail... |
FGFR1 amp NRAS amp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp NRAS over exp | Infigratinib | lung non-small cell carcinoma | decreased response | detail... |
FGFR1 amp NRAS over exp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Infigratinib | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | Infigratinib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Crizotinib + Filgotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171S ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171T | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174V | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1152R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK T1151dup ALK G1269A | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK amp | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK G1202R | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | CEP-28122 | lung non-small cell carcinoma | sensitive | detail... |
ALK negative | CEP-28122 | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK L1196M | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK S1206Y | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK C1156Y | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange | Alectinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Erlotinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Gefitinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Afatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK rearrange | Osimertinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Erlotinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Gefitinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Afatinib | lung non-small cell carcinoma | no benefit | detail... |
ROS1 rearrange | Osimertinib | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK F1174V ALK G1202R | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK F1174C | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
BRAF act mut | RAF709 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK I1171N ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK I1171N ALK D1203N | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK G1202R ALK L1204V ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK D1203N ALK E1210K ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
RET fusion | Selpercatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion ROS1 L1951R ROS1 L2026M | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 fusion ROS1 L1951R ROS1 L2026M | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK E1210K | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK S1206C ALK E1210K | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK F1174L ALK L1198V | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
ROS1 fusion KIT D816G | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK FGFR1 amp | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK HRAS amp | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF G469A | Encorafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF G469A | Dabrafenib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171N | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK I1171T | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK V1180L | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK V1180L | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171T | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK V1180L ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK D1203N | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF D594N | RMC-4550 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF N581D | RMC-4550 | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET rearrange | Ponatinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR1 V561M | Fexagratinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange TP53 mut | Crizotinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Ceritinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Alectinib | lung non-small cell carcinoma | decreased response | detail... |
ALK rearrange TP53 mut | Brigatinib | lung non-small cell carcinoma | decreased response | detail... |
BRAF mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1202R ALK G1269A | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
CDKN2A negative | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CDKN2A negative | Everolimus + Palbociclib | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A negative | Palbociclib + Sirolimus | lung non-small cell carcinoma | sensitive | detail... |
CDKN2A negative | Palbociclib + PF-04691502 | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK G1202R KIT amp | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600X | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E/K | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600K | Dabrafenib + Trametinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Brigatinib | lung non-small cell carcinoma | no benefit | detail... |
CDKN2A inact mut | Palbociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion | Ceritinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | MTI-31 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange TP53 mut | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange PIK3CA E545K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange ROS1 L2026M TP53 P278H | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
TP53 mutant | Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
TP53 mutant | Ipilimumab + Nivolumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1202R | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1202R | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202R | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK D1203N | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174C | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171X | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | Entrectinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK E1303K | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Ensartinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | PLB1003 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM del | AZD7648 + Olaparib | lung non-small cell carcinoma | sensitive | detail... |
ATM del | AZD7648 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK F1174C ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK T1151M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange | Crizotinib + Onalespib | lung non-small cell carcinoma | no benefit | detail... |
ALK C1156Y ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK F1174V ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK F1174L ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1196M ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK G1202R ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK I1171T ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK I1171S ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152R ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK amp ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152V ALK pos | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR1 amp | Zotatifin | lung non-small cell carcinoma | sensitive | detail... |
ATM del | Olaparib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600X | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600D | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600M | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600K | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF N581S | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF K601E | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF K601N | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G466A | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G469V | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
BRAF G596R | Vemurafenib | lung non-small cell carcinoma | no benefit | detail... |
TP53 R175H | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
TP53 Y220C | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
TP53 G245S | SLMP53-2 | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA mutant | Sulindac | lung non-small cell carcinoma | predicted - sensitive | detail... |
PIK3CA act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
PTEN inact mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
NRAS act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 act mut | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 S37F | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 S37C | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 D32V | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 G34V | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
CTNNB1 T41I | Osimertinib | lung non-small cell carcinoma | predicted - resistant | detail... |
TP53 mutant | Osimertinib | lung non-small cell carcinoma | not predictive | detail... |
TP53 inact mut | Osimertinib | lung non-small cell carcinoma | not predictive | detail... |
PIK3CA amp | Sulindac | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET fusion | Pralsetinib | lung non-small cell carcinoma | sensitive | detail... |
RET rearrange | Selpercatinib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK mutant | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK amp | Belizatinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR2 V514L | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR3 P573S | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
FGFR3 S756P | Fexagratinib | lung non-small cell carcinoma | no benefit | detail... |
TSC1 mutant | Vistusertib | lung non-small cell carcinoma | no benefit | detail... |
TSC2 mutant | Vistusertib | lung non-small cell carcinoma | no benefit | detail... |
RET rearrange | Pralsetinib | lung non-small cell carcinoma | sensitive | detail... |
PIK3CA E545K | T-2143 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G596V | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
NRAS Q61K | BI-3406 | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Pembrolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | Nivolumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | Atezolizumab | lung non-small cell carcinoma | not predictive | detail... |
BRAF mutant | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
BRAF amp | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
BRAF V600E | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
RET fusion | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
ROS1 fusion | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
RET mutant | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | unknown | detail... |
ALK positive | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E FGFR2 A553D | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E PIK3CA E545K | Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Ipilimumab + Nivolumab | lung non-small cell carcinoma | no benefit | detail... |
EML4 - ALK ALK I1171N | Gilteritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171N | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK I1171N | Entrectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Gilteritinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK TP53 Q331* | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 Q331* | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 V274fs | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 V274fs | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK TP53 Q331* | Alectinib + Ixazomib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK TP53 V274fs | Alectinib + Ixazomib | lung non-small cell carcinoma | sensitive | detail... |
TP53 Q331* | AZ32 + Radiotherapy | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + SHP099 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + Selumetinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib + RMC-4550 | lung non-small cell carcinoma | sensitive | detail... |
ALK fusion ALK T1151dup | Ceritinib | lung non-small cell carcinoma | no benefit | detail... |
ALK fusion ALK T1151dup | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | lung non-small cell carcinoma | not predictive | detail... |
ROS1 fusion ROS1 S1986F ROS1 L2000V | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 rearrange | Repotrectinib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK G1202del | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK F1174X | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | XMU-MP-5 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ROS1 rearrange | Crizotinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
NRAS Q61K | Lifirafenib + PD-0325901 | lung non-small cell carcinoma | sensitive | detail... |
NRAS Q61K | Lifirafenib + Pimasertib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Iruplinalkib | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | Ceritinib + Ribociclib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R | Ceritinib + HJC0152 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | HJC0152 | lung non-small cell carcinoma | sensitive | detail... |
FGFR1 amp | CPL304110 | lung non-small cell carcinoma | sensitive | detail... |
BRAF V600E | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF K601N | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466A | LTT462 + LXH 254 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Foritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion ALK C1156Y ALK L1198F | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK G1202R ALK L1204V ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK D1203N ALK E1210K ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK fusion ALK G1202R ALK S1206F ALK G1269A | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ROS1 fusion ROS1 G2032R | Taletrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | APG-2449 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange ALK L1196Q | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK E1129V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK amp | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK I1171S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174V | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174S | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E1129V | Ceritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171T ALK F1174V | Ceritinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E BRAF K601_W604del | Dabrafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | APG-2449 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | NUV-520 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | NUV-520 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Conteltinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK T1151M ALK G1202R | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK positive | Brigatinib | lung non-small cell carcinoma | no benefit | detail... |
ALK V1180L | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180Y | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171T ALK G1269A | Brigatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
SMARCA4 del | PRT3789 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM Q1919P | RP-3500 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | Carboplatin + Pembrolizumab + Pemetrexed Disodium | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Carboplatin + Paclitaxel + Pembrolizumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Lifirafenib + PD-0325901 | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET fusion | HS-10365 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E | Binimetinib + Encorafenib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Lorlatinib + PF-07284892 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R | Lorlatinib + PF-07284892 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion | Repotrectinib | lung non-small cell carcinoma | sensitive | detail... |
ATM Q1331H ATM I1441fs | Radiotherapy | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G466V | IHMT-RAF-128 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L597V NRAS Q61K | IHMT-RAF-128 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 rearrange | TQ-B3101 | lung non-small cell carcinoma | sensitive | detail... |
ROS1 fusion | TQ-B3139 | lung non-small cell carcinoma | predicted - sensitive | detail... |
SMARCA4 del | SMD-3040 | lung non-small cell carcinoma | sensitive | detail... |
ALK rearrange | TQ-B3139 | lung non-small cell carcinoma | sensitive | detail... |
PBRM1 mutant | unspecified PD-1 antibody | lung non-small cell carcinoma | predicted - resistant | detail... |
PBRM1 mutant | unspecified PD-L1 antibody | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF V600X | Tunlametinib + Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | Repotrectinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET amp | Selpercatinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
RET mutant | EP0031 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | SIJ777 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | SIJ777 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK T1151M | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK L1152V ALK G1269A | Ensartinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK E1210K | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK S1206F | Ensartinib | lung non-small cell carcinoma | predicted - resistant | detail... |
BRAF L485_P490delinsY | LXH 254 | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Encorafenib | lung non-small cell carcinoma | decreased response | detail... |
BRAF L485_P490delinsY | Sorafenib | lung non-small cell carcinoma | sensitive | detail... |
BRAF L485_P490delinsY | Ulixertinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF L485_P490delinsY | LXH 254 + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF L485_P490delinsY | Sorafenib + Trametinib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Ficonalkib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK | Afatinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y | Afatinib + Lorlatinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F | Afatinib + Crizotinib | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
ALK rearrange ALK G1202R | Ficonalkib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM inact mut | Ceralasertib + Durvalumab | lung non-small cell carcinoma | predicted - sensitive | detail... |
FGFR2 amp | CPL304110 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196P | Lorlatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1198R | Crizotinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1235R ALK C1237Y | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
FGFR2 fusion | ABSK061 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM mutant | M1774 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF G469A | PF-07799933 | lung non-small cell carcinoma | sensitive | detail... |
BRAF G466V | PF-07799933 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600E NRAS Q61K | PF-07799933 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1196M ALK G1202R | Brigatinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK P1094H | Alectinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196Q | Ceritinib | lung non-small cell carcinoma | predicted - resistant | detail... |
EML4 - ALK | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M | NVL-655 | lung non-small cell carcinoma | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Crizotinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Ceritinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Alectinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Brigatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
EML4 - ALK ALK T1151M ALK G1202R | Lorlatinib | lung non-small cell carcinoma | resistant | detail... |
SMARCA4 mutant | PRT3789 | lung non-small cell carcinoma | predicted - sensitive | detail... |
BRAF V600X | Cobimetinib + Vemurafenib | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ALK fusion ALK G1202R | NVL-655 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ATM inact mut | RP-3500 | lung non-small cell carcinoma | predicted - sensitive | detail... |
ROS1 rearrange | Foritinib | lung non-small cell carcinoma | sensitive | detail... |
RET fusion | SY-5007 | lung non-small cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00150657 | Phase II | Bevacizumab + Carboplatin + Gemcitabine | Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer | Unknown status | USA | 0 |
NCT00254319 | Phase II | Carboplatin Bevacizumab + Pemetrexed Disodium | Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | Unknown status | USA | 0 |
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00547105 | Phase II | Erlotinib | Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer | Completed | USA | 0 |
NCT00569296 | Phase I | Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT00585195 | Phase I | Crizotinib + Itraconazole Crizotinib + Rifampin | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) | Completed | USA | AUS | 2 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00828009 | Phase II | Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT00932451 | Phase II | Crizotinib | An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | Completed | USA | SWE | POL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUS | 6 |
NCT00950365 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium | Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT00975767 | Phase Ib/II | Docetaxel + Glesatinib Erlotinib + Glesatinib | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT00978250 | Phase II | 5-Fluoro-2-deoxycytidine + Tetrahydrouridine | A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | Completed | USA | 0 |
NCT00979212 | Phase II | Panitumumab Carboplatin + Paclitaxel | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) | Completed | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT00997334 | Phase II | Erlotinib | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | Completed | USA | 0 |
NCT01005797 | Phase I | Panobinostat + Sorafenib | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | Completed | USA | 0 |
NCT01014598 | Phase I | Cisplatin | Cisplatin in Treating Patients With Lung Cancer | Completed | USA | 0 |
NCT01059552 | Phase I | Vorinostat | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01061788 | Phase I | Everolimus + Ganitumab + Panitumumab | A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer | Completed | USA | 0 |
NCT01107626 | Phase III | Pemetrexed Disodium Bevacizumab | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01179269 | Phase II | Paclitaxel + Pazopanib | Stage IIIB/IV Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT01210378 | Phase II | Nitroglycerin | Nitroglycerin in Non-small Cell Lung Cancer | Terminated | NLD | 0 |
NCT01233687 | Phase Ib/II | Rilotumumab Erlotinib | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01248247 | Phase I | Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study | Completed | USA | 0 |
NCT01263782 | Phase II | Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab | BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | Completed | USA | 0 |
NCT01288430 | Phase I | DS-2248 | A Study of DS-2248, in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | POL | ESP | 0 |
NCT01336634 | Phase II | Dabrafenib Dabrafenib + Trametinib | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Completed | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | 3 |
NCT01336842 | Phase I | Cisplatin Panobinostat Pemetrexed Disodium | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Completed | USA | 0 |
NCT01344824 | Phase II | Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers | Completed | USA | 0 |
NCT01351415 | Phase III | Bevacizumab | A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer | Completed | USA | SVK | NLD | LBN | ITA | GRC | FRA | ESP | DNK | DEU | BRA | BEL | AUT | ARG | 4 |
NCT01383148 | Phase Ib/II | MVA-MUC1-IL2 vaccine | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | 0 |
NCT01386385 | Phase Ib/II | Carboplatin + Paclitaxel Carboplatin + Etoposide + Veliparib | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01391533 | Phase I | SAR125844 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors | Completed | USA | ITA | FRA | ESP | 0 |
NCT01449461 | Phase Ib/II | Brigatinib | A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | Completed | 0 | |
NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
NCT01455389 | Phase Ib/II | Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone | FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer | Terminated | USA | 0 |
NCT01456325 | Phase III | Erlotinib Onartuzumab | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) | Completed | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01465802 | Phase II | Dacomitinib Alclometasone Doxycycline | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | Completed | USA | 1 |
NCT01487265 | Phase II | Buparlisib + Erlotinib | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | Completed | USA | 0 |
NCT01493843 | Phase II | Carboplatin Pictilisib Bevacizumab | Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | Completed | USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 3 |
NCT01514864 | Phase II | Dasatinib | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Terminated | USA | POL | GBR | DEU | CAN | BRA | 1 |
NCT01526928 | Phase Ib/II | Rociletinib | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | Terminated | USA | POL | FRA | AUS | 0 |
NCT01532089 | Phase II | Bevacizumab Bevacizumab + Erlotinib | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | Completed | USA | 0 |
NCT01537744 | Phase I | Azacitidine + Romidepsin | A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01545947 | Phase I | Azacitidine + Onatasertib Erlotinib + Onatasertib | Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer | Completed | USA | ESP | 0 |
NCT01553942 | Phase II | Afatinib Cisplatin Pemetrexed Disodium | Afatinib With CT and RT for EGFR-Mutant NSCLC | Active, not recruiting | USA | 0 |
NCT01573702 | Phase II | Erlotinib | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | Completed | USA | 0 |
NCT01574729 | Phase II | rAD-p53 | Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma | Unknown status | 1 | |
NCT01578551 | Phase II | Metformin Carboplatin + Paclitaxel Bevacizumab | A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | Terminated | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01620190 | Phase II | Nab-paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01628471 | Phase Ib/II | Decitabine + Genistein | MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Completed | CAN | 0 |
NCT01630733 | Phase III | Docetaxel Custirsen + Docetaxel | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | Unknown status | USA | POL | NZL | ITA | ISR | HUN | ESP | DEU | AUS | 6 |
NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01646125 | Phase II | Docetaxel Luminespib Pemetrexed Disodium | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | Terminated | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | 4 |
NCT01647711 | Phase I | Afatinib | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | Completed | USA | 0 |
NCT01649284 | Phase I | Afatinib | Afatinib Expanded Access Program | Approved for marketing | USA | 0 |
NCT01649947 | Phase II | Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel Carboplatin + Hydroxychloroquine + Paclitaxel | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | Completed | USA | 0 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT01664754 | Phase I | Pemetrexed Disodium Carboplatin Exemestane | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01676714 | Phase II | Dovitinib | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01700400 | Phase I | Carboplatin Everolimus Bevacizumab Pemetrexed Disodium | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | Completed | USA | 0 |
NCT01708993 | Phase II | Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep | Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | Completed | CAN | 0 |
NCT01712217 | Phase Ib/II | Crizotinib Onalespib | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | Completed | USA | FRA | ESP | CAN | 1 |
NCT01717482 | Phase II | Metformin | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT01720836 | Phase Ib/II | MUC1 peptide-Poly-ICLC vaccine | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01723800 | Phase I | Buparlisib + Carboplatin + Pemetrexed Disodium | PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01725165 | Phase II | Oligometastatic Disease | Completed | USA | CAN | 0 | |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01746251 | Phase II | Afatinib | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | Unknown status | USA | 0 |
NCT01750281 | Phase II | Docetaxel Docetaxel + Selumetinib | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. | Completed | USA | POL | NLD | HUN | FRA | DEU | BRA | BGR | 0 |
NCT01752400 | Phase II | Luminespib | AUY922 for Advanced ALK-positive NSCLC | Completed | USA | 0 |
NCT01769391 | Phase II | Necitumumab Carboplatin + Paclitaxel | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | Completed | USA | POL | DEU | 3 |
NCT01772797 | Phase I | Ceritinib Luminespib | Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | Completed | USA | ITA | ESP | AUS | 1 |
NCT01783197 | Phase I | Selumetinib | Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | Completed | CAN | 0 |
NCT01784640 | Phase I | Luminespib + Pemetrexed Disodium | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01788566 | Phase II | Cisplatin + Gemcitabine + Necitumumab | A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer | Completed | USA | NLD | FRA | ESP | CAN | 2 |
NCT01798485 | Phase III | Ganetespib Docetaxel | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | Terminated | USA | SVN | ROU | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 5 |
NCT01801111 | Phase II | Erlotinib Alectinib | A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment | Completed | USA | SWE | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | BEL | AUS | 4 |
NCT01802632 | Phase Ib/II | Osimertinib | AZD9291 First Time In Patients Ascending Dose Study (AURA) | Completed | USA | ITA | GBR | FRA | ESP | DEU | AUS | 3 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01813734 | Phase II | Ponatinib | Ponatinib in Advanced NSCLC w/ RET Translocations | Completed | USA | 0 |
NCT01820754 | Phase II | Cisplatin Ipilimumab Carboplatin Paclitaxel | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT01822496 | Phase II | Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT01828112 | Phase III | Docetaxel Pemetrexed Disodium Ceritinib | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | Completed | USA | TUR | NLD | LBN | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 6 |
NCT01829217 | Phase II | Sunitinib | Sunitinib in Never-Smokers With Lung Adenocarcinoma | Completed | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | CHE | 0 |
NCT01833143 | Phase II | Bortezomib | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D | Completed | USA | 0 |
NCT01837329 | Phase I | Tetrathiomolybdate | Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01839955 | Phase Ib/II | Erlotinib + Quinacrine | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01848756 | Phase Ib/II | SNX-5422 | Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers | Terminated | USA | 0 |
NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01854034 | Phase II | Luminespib | Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | Completed | USA | 0 |
NCT01857271 | Phase II | Erlotinib | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT01858389 | Phase II | Dacomitinib | A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT01859026 | Phase I | Binimetinib + Erlotinib | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | Completed | USA | 0 |
NCT01866410 | Phase II | Cabozantinib + Erlotinib | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01868022 | Phase I | Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Completed | USA | NLD | GBR | ESP | DNK | BEL | 1 |
NCT01871805 | Phase Ib/II | Alectinib | A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | GBR | ESP | CAN | 0 |
NCT01887886 | Phase III | Erlotinib + Onartuzumab | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation | Completed | USA | FRA | ESP | DEU | 4 |
NCT01892046 | Phase I | Carboplatin SNX-5422 Paclitaxel | Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors | Completed | USA | 0 |
NCT01900652 | Phase II | Emibetuzumab + Erlotinib Emibetuzumab | A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants | Completed | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL | 1 |
NCT01903993 | Phase II | Atezolizumab | A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | Completed | USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 2 |
NCT01911325 | Phase Ib/II | Buparlisib Docetaxel | Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | Terminated | USA | SWE | ITA | FRA | ESP | DEU | BEL | 1 |
NCT01911507 | Phase I | Capmatinib + Erlotinib | INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT01912625 | Phase I | Carboplatin + Paclitaxel + Trametinib | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01928160 | Phase II | Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | Withdrawn | 0 | |
NCT01928576 | Phase II | Nivolumab Entinostat Azacitidine | Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. | Completed | USA | 0 |
NCT01933932 | Phase III | Docetaxel + Selumetinib | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
NCT01935947 | Phase II | Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT01946789 | Phase I | Nogapendekin alfa inbakicept | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01947608 | Phase I | Ceritinib | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | No longer available | USA | ARG | 8 |
NCT01951690 | Phase II | Defactinib | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT01957007 | Phase I | Docetaxel + Vantictumab | A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | Completed | USA | 0 |
NCT01966003 | Phase III | Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer | Completed | USA | BGR | AUS | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01967095 | Phase I | Erlotinib | Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer | Completed | USA | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01970865 | Phase II | Lorlatinib Crizotinib | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 5 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | CHE | 2 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT01993810 | Phase III | Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | Active, not recruiting | USA | 0 |
NCT01998126 | Phase I | Erlotinib + Ipilimumab Crizotinib + Ipilimumab | Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts | Completed | USA | 0 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01999985 | Phase I | Afatinib + Dasatinib | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02000947 | Phase Ib/II | Durvalumab + Tremelimumab | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 2 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | NLD | GBR | FRA | FIN | ESP | DNK | CHE | 0 |
NCT02008227 | Phase III | Docetaxel Atezolizumab | A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK | Completed | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | AUT | ARG | 11 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02013219 | Phase I | Alectinib + Atezolizumab Atezolizumab + Erlotinib | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | 2 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02019979 | Phase II | Metformin | Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) | Terminated | USA | 0 |
NCT02022982 | Phase Ib/II | Palbociclib + PD-0325901 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | Completed | USA | 0 |
NCT02031458 | Phase II | Atezolizumab | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH | Completed | USA | TUR | SVN | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUS | 5 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02039674 | Phase Ib/II | Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Disodium Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) | Completed | 0 | |
NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02044601 | Phase Ib/II | Carboplatin + Onartuzumab + Paclitaxel Carboplatin + Erlotinib + Onartuzumab + Paclitaxel | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | Withdrawn | USA | 0 |
NCT02045446 | Phase II | Bevacizumab + Erlotinib Docetaxel + Gemcitabine | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02047344 | Phase II | Antroquinonol | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | Completed | USA | 1 |
NCT02066636 | Phase III | Nivolumab | A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) | Completed | USA | CAN | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02075840 | Phase III | Alectinib Crizotinib | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS | 16 |
NCT02079636 | Phase I | LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab | A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | Completed | USA | ESP | 0 |
NCT02080078 | Phase I | Erlotinib + Theophylline | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | Terminated | CAN | 0 |
NCT02085070 | Phase II | Pembrolizumab | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | Completed | USA | 0 |
NCT02087176 | Phase II | Adavosertib Pegfilgrastim | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | Terminated | USA | 0 |
NCT02087241 | Phase II | Adavosertib Carboplatin + Pemetrexed Disodium | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | Terminated | USA | 0 |
NCT02087423 | Phase II | Durvalumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) | Active, not recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 6 |
NCT02088112 | Phase I | Durvalumab + Gefitinib | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | Completed | USA | 2 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02094573 | Phase II | Brigatinib | A Phase 2, Multicenter, Randomized Study of AP26113 | Completed | 0 | |
NCT02106546 | Phase III | Veliparib Carboplatin + Paclitaxel | Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Completed | USA | TUR | SWE | SVK | POL | NZL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 9 |
NCT02108964 | Phase Ib/II | Nazartinib | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | Completed | USA | NLD | ESP | DEU | CAN | 4 |
NCT02109016 | Phase II | Lucitanib | A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | 0 |
NCT02113813 | Phase I | Naquotinib | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | Completed | USA | 0 |
NCT02115464 | Phase II | Metformin | Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy | Terminated | CAN | 0 |
NCT02117024 | Phase II | Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02119650 | Phase II | Cisplatin + Pemetrexed Disodium + Ruxolitinib Cisplatin + Pemetrexed Disodium | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02125461 | Phase III | Durvalumab | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) | Completed | USA | TUR | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 10 |
NCT02132598 | Phase II | Cabozantinib | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Terminated | USA | 0 |
NCT02133196 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02134015 | Phase III | Erlotinib Erlotinib + Patritumab | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | Terminated | USA | POL | ITA | HUN | GBR | ESP | DEU | CZE | CAN | BEL | 0 |
NCT02134886 | Phase I | Erlotinib | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | Terminated | USA | 0 |
NCT02134912 | Phase II | Crizotinib + Pemetrexed Disodium Pemetrexed Disodium | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | Terminated | USA | 0 |
NCT02142738 | Phase III | Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Completed | 0 | |
NCT02143466 | Phase I | Osimertinib + Savolitinib Osimertinib + Selumetinib Durvalumab + Osimertinib | AZD9291 in Combination With Ascending Doses of Novel Therapeutics | Active, not recruiting | USA | POL | CAN | 5 |
NCT02147990 | Phase II | Rociletinib | TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 3 |
NCT02151981 | Phase III | Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Osimertinib | AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) | Active, not recruiting | USA | SWE | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
NCT02152631 | Phase III | Erlotinib Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | ARG | 7 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | GBR | 0 |
NCT02157883 | Phase I | Osimertinib Itraconazole + Osimertinib | Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | Completed | USA | NLD | GBR | BEL | 2 |
NCT02163733 | Phase I | Osimertinib | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | Completed | GBR | FRA | ESP | 1 |
NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | NLD | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02179671 | Phase II | Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | Completed | USA | 0 |
NCT02183883 | Phase II | Afatinib | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1) | Completed | GBR | 0 |
NCT02186301 | Phase II | Rociletinib Erlotinib | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | Terminated | USA | ITA | ESP | DEU | 3 |
NCT02186847 | Phase II | Metformin Carboplatin + Paclitaxel | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | ISR | CAN | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02192541 | Phase I | Aflibercept + Ganetespib | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | Terminated | USA | 0 |
NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
NCT02193282 | Phase III | Erlotinib | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | Active, not recruiting | USA | 1 |
NCT02194738 | Phase I | Nivolumab Crizotinib Erlotinib | Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Recruiting | USA | 2 |
NCT02197234 | Phase I | Osimertinib + Simvastatin Simvastatin Osimertinib | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | Completed | USA | FRA | ESP | BEL | 1 |
NCT02197247 | Phase I | Osimertinib + Rifampin Osimertinib | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | Completed | USA | NLD | GBR | ESP | 2 |
NCT02201992 | Phase III | Crizotinib | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | Recruiting | USA | 2 |
NCT02206763 | Phase I | Erlotinib + Momelotinib | Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02220894 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | Completed | 0 | |
NCT02221739 | Phase II | Ipilimumab | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02225405 | Phase I | Cisplatin + Docetaxel + Nintedanib | Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) | Completed | USA | 0 |
NCT02228369 | Phase I | Osimertinib AZD3759 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) | Completed | USA | AUS | 2 |
NCT02250326 | Phase II | Azacitidine + Nab-paclitaxel Nab-paclitaxel | Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT02257619 | Phase II | Docetaxel Itacitinib | Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02258607 | Phase I | Momelotinib Momelotinib + Trametinib | Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | Terminated | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02259582 | Phase II | Carboplatin + Pemetrexed Disodium Demcizumab | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ESP | BEL | AUS | 0 |
NCT02259621 | Phase II | Nivolumab | Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC | Active, not recruiting | USA | CAN | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02264990 | Phase III | Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers | Completed | USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG | 5 |
NCT02271139 | Phase III | Alectinib | Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib | No longer available | USA | 0 |
NCT02271906 | Phase II | Afatinib | The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting | Terminated | USA | 0 |
NCT02272413 | Phase III | Carboplatin + Paclitaxel Bevacizumab | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer | Completed | USA | TUR | ROU | POL | ITA | HUN | HRV | GRC | GBR | ESP | DEU | BRA | BGR | ARG | 14 |
NCT02273375 | Phase III | Durvalumab | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Active, not recruiting | USA | ROU | POL | NZL | NLD | ITA | HUN | FRA | ESP | CAN | BRA | BGR | AUS | 6 |
NCT02277457 | Phase I | Crizotinib Erlotinib | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations | Withdrawn | USA | 0 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02283320 | Phase II | Docetaxel | A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT02289833 | Phase II | Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | USA | POL | ITA | ESP | DEU | CHE | 1 |
NCT02292550 | Phase Ib/II | Ceritinib + Ribociclib | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | Completed | USA | ITA | FRA | ESP | 2 |
NCT02296125 | Phase III | Erlotinib Osimertinib Gefitinib | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | 11 |
NCT02298153 | Phase I | Atezolizumab + Epacadostat | A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02299141 | Phase I | Nintedanib | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02299505 | Phase I | Ceritinib | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | POL | NLD | LBN | ITA | GRC | GBR | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | 7 |
NCT02303990 | Phase I | Pembrolizumab | RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Completed | USA | 0 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02309892 | Phase I | Carboplatin + L-DOS47 + Pemetrexed Disodium | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | Terminated | USA | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
NCT02314364 | Phase II | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | Completed | USA | 0 | |
NCT02314481 | Phase II | Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) | Active, not recruiting | GBR | 0 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02316002 | Phase II | Pembrolizumab | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02317016 | Phase I | Osimertinib Rosuvastatin | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | Completed | USA | GBR | FRA | ESP | 0 |
NCT02318368 | Phase II | Erlotinib Erlotinib + Ficlatuzumab | A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label | Terminated | USA | ITA | AUS | 4 |
NCT02318771 | Phase I | Pembrolizumab | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02321293 | Phase I | Erlotinib + Gefitinib | A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC | Unknown status | CAN | 0 |
NCT02321501 | Phase I | Ceritinib + Everolimus | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02321540 | Phase Ib/II | Ibrutinib | A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02322281 | Phase III | Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib | TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT02323126 | Phase II | Nazartinib + Nivolumab Capmatinib + Nivolumab | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | CHE | AUS | 1 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02335944 | Phase Ib/II | Capmatinib + Nazartinib | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | Terminated | USA | NOR | ITA | FRA | ESP | DEU | CAN | AUS | 3 |
NCT02336451 | Phase II | Ceritinib | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges | Completed | USA | TUR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
NCT02337530 | Phase II | Selumetinib Cisplatin + Pemetrexed Disodium | Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer | Completed | CAN | 0 |
NCT02342353 | Phase Ib/II | Erlotinib + Pacritinib | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | Terminated | USA | 0 |
NCT02343952 | Phase II | Pembrolizumab | Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | Completed | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02349633 | Phase II | Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Terminated | USA | AUS | 2 |
NCT02350764 | Phase II | Ipilimumab + Nivolumab | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | Completed | USA | 0 |
NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
NCT02355431 | Phase II | Erlotinib Itacitinib | INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | Withdrawn | USA | 0 |
NCT02357836 | Phase I | Itraconazole | Neoadjuvant Itraconazole in Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02364609 | Phase I | Afatinib + Pembrolizumab | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | Completed | USA | 0 |
NCT02364999 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | Completed | USA | TUR | ROU | POL | NLD | ITA | HUN | HRV | GRC | FRA | ESP | DEU | CZE | BRA | BGR | AUS | 11 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02366143 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel | TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | Completed | USA | SVK | NLD | LVA | LTU | ITA | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT02367781 | Phase III | Atezolizumab Carboplatin + Nab-paclitaxel | A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer | Completed | USA | ITA | ISR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02367794 | Phase III | Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab | A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | SVK | NLD | LVA | LTU | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT02381314 | Phase I | Ipilimumab + MGA271 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | Completed | USA | 0 |
NCT02382406 | Phase Ib/II | Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | Terminated | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02387216 | Phase II | Seribantumab Pemetrexed Disodium Docetaxel | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | Terminated | USA | HUN | FRA | ESP | DEU | CAN | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02392507 | Phase II | Carboplatin + Nab-paclitaxel + Necitumumab | A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | Completed | USA | 0 |
NCT02393625 | Phase I | Ceritinib + Nivolumab | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | ESP | CAN | BEL | AUS | 2 |
NCT02395172 | Phase III | Avelumab Docetaxel | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | Completed | USA | TUR | SVK | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DNK | CZE | CHE | BRA | BGR | BEL | AUS | ARG | 9 |
NCT02400814 | Phase I | Atezolizumab | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02403193 | Phase Ib/II | Spartalizumab + Taminadenant Taminadenant | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) | Completed | USA | 0 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN | 2 |
NCT02407171 | Phase Ib/II | Pembrolizumab | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Completed | USA | 0 |
NCT02409342 | Phase III | Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin | A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | 7 |
NCT02409355 | Phase III | Carboplatin Cisplatin Gemcitabine Atezolizumab | A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer | Terminated | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | 3 |
NCT02411448 | Phase III | Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) | Active, not recruiting | USA | TUR | ROU | ITA | GRC | GBR | FRA | ESP | DEU | CAN | 4 |
NCT02412371 | Phase II | Veliparib Carboplatin + Paclitaxel | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02414139 | Phase II | Capmatinib | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) | Completed | USA | SWE | NOR | NLD | LBN | ITA | ISR | GBR | FRA | ESP | DEU | BEL | AUT | ARG | 6 |
NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | USA | 0 |
NCT02422381 | Phase Ib/II | Gemcitabine Pembrolizumab | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02422589 | Phase I | Warfarin Midazolam Ceritinib | A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | Completed | USA | ITA | ESP | DNK | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT02424617 | Phase Ib/II | Bemcentinib + Erlotinib | A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435121 | Phase II | SAR125844 | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | Completed | BEL | 0 |
NCT02437136 | Phase Ib/II | Entinostat + Pembrolizumab | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma | Completed | USA | 0 |
NCT02438722 | Phase II | Afatinib Afatinib + Cetuximab | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02439450 | Phase I | HS-110 Nivolumab | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT02444741 | Phase Ib/II | Pembrolizumab | MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02448251 | Phase I | Abivertinib | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | Terminated | USA | FRA | ESP | 0 |
NCT02448303 | Phase II | Acalabrutinib Pembrolizumab | Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02450539 | Phase II | Abemaciclib Docetaxel | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | DEU | AUS | 4 |
NCT02451852 | Phase I | Osimertinib | AZD9291 US Expanded Access Program | No longer available | USA | 0 |
NCT02451865 | Phase I | Binimetinib + Docetaxel | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02451930 | Phase I | Necitumumab Pembrolizumab | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | Completed | USA | FRA | ESP | 1 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 6 |
NCT02454842 | Phase II | TH-4000 | Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC | Terminated | USA | AUS | 0 |
NCT02454933 | Phase III | Osimertinib Durvalumab | Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) | Completed | CAN | 2 |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02460367 | Phase Ib/II | Docetaxel + Indoximod | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02463994 | Phase I | Atezolizumab | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | Completed | USA | 0 |
NCT02468661 | Phase I | Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | Terminated | USA | NLD | ITA | FRA | ESP | DEU | BEL | 3 |
NCT02469701 | Phase II | Nivolumab | BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | Terminated | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02474355 | Phase III | Osimertinib | Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC | Completed | SWE | ITA | IRL | GBR | ESP | DNK | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT02475213 | Phase I | MGA271 + Pembrolizumab | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | Completed | USA | 0 |
NCT02475382 | Expanded access | Nivolumab | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) | No longer available | CAN | BRA | 0 |
NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT02485652 | Phase II | Olmutinib | Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | Terminated | USA | ITA | ESP | DEU | CAN | AUS | 4 |
NCT02486718 | Phase III | Atezolizumab | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02489903 | Phase II | Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel | RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens | Completed | USA | 0 |
NCT02492867 | Phase 0 | Durvalumab Carboplatin + Paclitaxel | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02495636 | Phase II | Atezolizumab + Rasdegafusp alfa | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02496663 | Phase I | Necitumumab + Osimertinib | Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | Active, not recruiting | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500199 | Phase I | Pyrotinib | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | Unknown status | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02503722 | Phase I | Osimertinib + Sapanisertib | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02504372 | Phase III | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) | Active, not recruiting | 0 | |
NCT02504489 | Phase III | Docetaxel Docetaxel + Plinabulin | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) | Completed | USA | AUS | 1 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02511106 | Phase III | Osimertinib | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 9 |
NCT02511184 | Phase I | Crizotinib Pembrolizumab | Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients | Terminated | USA | 0 |
NCT02514174 | FDA approved | Afatinib | Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older | Completed | USA | 0 |
NCT02516813 | Phase I | Peposertib | Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy | Completed | USA | SWE | NOR | NLD | DNK | DEU | CHE | BEL | 0 |
NCT02520778 | Phase I | Navitoclax + Osimertinib | Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02521051 | Phase Ib/II | Bevacizumab Alectinib | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT02523469 | Phase Ib/II | Nivolumab + Nogapendekin alfa inbakicept | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02525757 | Phase II | Atezolizumab Carboplatin + Paclitaxel | MPDL3280A With Chemoradiation for Lung Cancer | Active, not recruiting | USA | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02535338 | Phase Ib/II | Erlotinib + Onalespib | Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02537561 | Phase I | Talazoparib Cisplatin + Gemcitabine | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | Withdrawn | 0 | |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02542293 | Phase III | Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ISR | GRC | GBR | FIN | DNK | BRA | BGR | ARG | 16 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02544633 | Phase II | Glesatinib | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | Completed | USA | POL | ITA | HUN | GBR | CAN | AUS | 2 |
NCT02546986 | Phase II | Azacitidine + Pembrolizumab Pembrolizumab | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | GRC | FRA | ESP | DEU | 0 |
NCT02547675 | Phase I | Rociletinib | Rociletinib (CO-1686) USA Expanded Access Program | No longer available | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02563548 | Phase I | PEGPH20 + Pembrolizumab | Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab | Completed | USA | 0 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | ITA | ISR | FRA | ESP | DEU | 2 |
NCT02573259 | Phase I | PF-06801591 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | Completed | USA | POL | BGR | 4 |
NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Completed | USA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line NSCLC (JAVELIN Lung 100) | Completed | USA | TUR | SVK | ROU | POL | NZL | NLD | LTU | LBN | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CYP | CAN | BRA | BGR | BEL | AUS | 14 |
NCT02576665 | Phase I | Toca FC + Vocimagene amiretrorepvec | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02578680 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | Completed | 0 | |
NCT02580708 | Phase Ib/II | Trametinib Rociletinib | A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02581787 | Phase Ib/II | Fresolimumab | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02581943 | Phase II | Paclitaxel Pembrolizumab Carboplatin | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02584634 | Phase I | Crizotinib Avelumab Lorlatinib | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | Terminated | USA | ESP | AUS | 2 |
NCT02588261 | Phase III | Naquotinib Gefitinib Erlotinib | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | Terminated | USA | ROU | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT02589522 | Phase I | Berzosertib | VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02591615 | Phase II | Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium | Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | Completed | USA | 0 |
NCT02592577 | Phase I | MAGE A10c796T for Advanced NSCLC | Completed | USA | GBR | ESP | CAN | 0 | |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02595944 | Phase III | Nivolumab | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) | Active, not recruiting | USA | 0 |
NCT02599454 | Phase I | Atezolizumab | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02605746 | Phase I | Ceritinib | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | Completed | USA | 0 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | CHE | CAN | 4 |
NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02609776 | Phase I | Amivantamab-vmjw Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Lazertinib | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | AUS | 4 |
NCT02616393 | Phase II | Tesevatinib | Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases | Completed | USA | 0 |
NCT02621398 | Phase I | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02630186 | Phase Ib/II | Atezolizumab + Rociletinib | A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | Terminated | USA | 0 |
NCT02635061 | Phase I | Citarinostat + Ipilimumab + Nivolumab | Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02637531 | Phase I | Pembrolizumab Eganelisib | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Unknown status | USA | 0 |
NCT02638090 | Phase Ib/II | Pembrolizumab Vorinostat | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Completed | USA | 0 |
NCT02639091 | Phase I | Anetumab ravtansine + Cisplatin + Pemetrexed Disodium | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | Completed | USA | ITA | 0 |
NCT02639234 | Phase II | FANG vaccine + Nivolumab | Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT02640508 | Phase II | Eribulin + Lenvatinib | Eribulin and Lenvatinib in Advanced Solid Tumors | Completed | USA | 0 |
NCT02642042 | Phase II | Docetaxel + Trametinib | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02642939 | Phase II | Mifepristone | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02648724 | Phase Ib/II | SYM015 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | Completed | USA | ESP | DNK | 3 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02654587 | Phase III | OSE 2101 Pemetrexed Disodium Docetaxel | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT02658097 | Phase II | Pembrolizumab | A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Completed | USA | 0 |
NCT02659059 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) | Completed | USA | CAN | 0 |
NCT02664181 | Phase II | Nivolumab Decitabine + Nivolumab + Tetrahydrouridine | Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) | Completed | USA | 0 |
NCT02665416 | Phase I | RO5520985 + Selicrelumab Bevacizumab + Selicrelumab | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors | Completed | USA | NLD | ITA | ESP | DNK | CAN | BEL | 0 |
NCT02666105 | Phase II | Exemestane | Exemestane in Post-Menopausal Women With NSCLC | Completed | USA | 0 |
NCT02669914 | Phase II | Durvalumab | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Terminated | USA | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02681549 | Phase II | Bevacizumab + Pembrolizumab | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02684461 | Phase II | Pembrolizumab | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | Completed | USA | 0 |
NCT02695290 | Phase III | Afatinib | Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) | Terminated | USA | 0 |
NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02706626 | Phase II | Brigatinib | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Terminated | USA | 0 |
NCT02710396 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Genetic Predictors of Benefit to Pembrolizumab | Terminated | USA | 0 |
NCT02713529 | Phase Ib/II | AMG 820 + Pembrolizumab | Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02713828 | Phase Ib/II | Glembatumumab vedotin | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | Terminated | USA | 0 |
NCT02713867 | Phase III | Nivolumab | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 0 |
NCT02715284 | Phase I | Dostarlimab-gxly | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | ARG | 2 |
NCT02716038 | Phase II | Atezolizumab + Carboplatin + Nab-paclitaxel | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | Completed | USA | 0 |
NCT02716116 | Phase Ib/II | Mobocertinib | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ITA | GBR | ESP | DEU | 5 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02730247 | Phase II | Nab-paclitaxel + Ramucirumab | Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02733250 | Phase Ib/II | Nab-paclitaxel + Pembrolizumab | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) | Completed | CAN | 0 |
NCT02737501 | Phase III | Brigatinib Crizotinib | ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L) | Completed | USA | SWE | NOR | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 4 |
NCT02740985 | Phase I | AZD4635 AZD4635 + Durvalumab | A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies | Completed | USA | 0 |
NCT02750215 | Phase II | Capmatinib | A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor | Completed | USA | 0 |
NCT02750514 | Phase II | Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) | Terminated | USA | ITA | FRA | ESP | CHE | CAN | AUT | AUS | 0 |
NCT02767804 | Phase III | Crizotinib Ensartinib | eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT02768558 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | Terminated | USA | 0 |
NCT02770014 | Phase II | Erlotinib | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Terminated | USA | 0 |
NCT02775435 | Phase III | Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | Completed | 0 | |
NCT02779751 | Phase II | Abemaciclib + Pembrolizumab | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | BEL | 1 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02784158 | Phase I | Brigatinib | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | No longer available | USA | 0 |
NCT02789345 | Phase I | Osimertinib + Ramucirumab Necitumumab + Osimertinib | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | Completed | USA | FRA | ESP | 2 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT02803203 | Phase Ib/II | Bevacizumab + Osimertinib | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | Completed | USA | 0 |
NCT02805660 | Phase Ib/II | Durvalumab + Mocetinostat | Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | Terminated | USA | 0 |
NCT02812667 | Phase I | Nivolumab + Plinabulin | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT02817633 | Phase I | Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Recruiting | USA | ESP | 2 |
NCT02818426 | Phase Ib/II | UCPVax | Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (UCPVax) | Active, not recruiting | FRA | 0 |
NCT02818920 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab | Active, not recruiting | USA | 0 |
NCT02823990 | Phase II | MVA-MUC1-IL2 vaccine + Nivolumab | TG4010 and Nivolumab in Patients With Lung Cancer | Completed | USA | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02826161 | Phase III | Napabucasin + Paclitaxel Paclitaxel | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) | Terminated | USA | 0 |
NCT02829099 | Phase I | JNJ-64457107 | A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | Completed | ISR | ESP | 0 |
NCT02831491 | Phase II | Docetaxel + Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT02831933 | Phase II | AdV-tk + Nivolumab | Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) | Terminated | USA | 0 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | GBR | ESP | 0 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02840994 | Phase Ib/II | CV301 + Nivolumab Nivolumab | A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02846792 | Phase Ib/II | Nivolumab + Plinabulin | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02848651 | Phase II | Atezolizumab | A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] | Completed | USA | 0 |
NCT02855125 | Phase II | Tegafur-gimeracil-oteracil Potassium TAS-114 + Tegafur-gimeracil-oteracil Potassium | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | Completed | USA | POL | ITA | FRA | ESP | 1 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02858869 | Phase 0 | Pembrolizumab | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Completed | USA | 0 |
NCT02860780 | Phase I | Prexasertib + Ralimetinib | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Completed | USA | DEU | 0 |
NCT02864251 | Phase III | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) | Completed | USA | FRA | ESP | CAN | 6 |
NCT02869789 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | Completed | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | ARG | 3 |
NCT02879617 | Phase II | Durvalumab | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Completed | USA | 0 |
NCT02879760 | Phase Ib/II | Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Completed | CAN | 0 |
NCT02879994 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | NLD | GBR | ESP | DEU | 2 |
NCT02897375 | Phase I | Cisplatin + Palbociclib Carboplatin + Palbociclib | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | Completed | USA | 0 |
NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
NCT02898116 | Phase Ib/II | Durvalumab + Ensartinib Ensartinib | A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | 2 |
NCT02904954 | Phase II | Durvalumab | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02912949 | Phase Ib/II | Zenocutuzumab | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Recruiting | USA | SWE | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 4 |
NCT02917993 | Phase Ib/II | Itacitinib + Osimertinib | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ESP | 2 |
NCT02919449 | Phase I | Atezolizumab + MV-NIS | Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02920450 | Phase Ib/II | Carboplatin + Gedatolisib + Paclitaxel | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | Terminated | USA | 0 |
NCT02920996 | Phase II | Merestinib | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | Terminated | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02922777 | Phase I | Bemcentinib + Docetaxel | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | Completed | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT02926768 | Phase Ib/II | CK-101 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | Completed | USA | POL | NZL | AUS | 1 |
NCT02927301 | Phase II | Atezolizumab | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02927340 | Phase II | Lorlatinib | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | Unknown status | USA | 0 |
NCT02941601 | Phase II | Carboplatin + Gemcitabine + Necitumumab | A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | USA | ROU | ITA | GBR | DEU | BEL | 1 |
NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Completed | USA | 0 |
NCT02944396 | Phase II | Carboplatin + Paclitaxel + Pemetrexed Disodium + Veliparib Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Veliparib | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02947386 | Phase Ib/II | Nimotuzumab + Nivolumab | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02949843 | Phase II | Nivolumab + Pembrolizumab | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | Terminated | USA | 0 |
NCT02950038 | Phase II | Ibrutinib + Nivolumab | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02952729 | Phase I | XMT-1522 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | Completed | USA | 0 |
NCT02952989 | Phase I | SGN-2FF | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02954523 | Phase Ib/II | Dasatinib + Osimertinib | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Terminated | USA | 0 |
NCT02954991 | Phase II | Nivolumab + Sitravatinib Mocetinostat + Nivolumab Glesatinib + Nivolumab | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT02955290 | Phase Ib/II | CIMAvax-EGF + Nivolumab | CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02955758 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02959437 | Phase Ib/II | Azacitidine + Epacadostat + Pembrolizumab | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Terminated | USA | GBR | ESP | 0 |
NCT02963610 | Phase Ib/II | Lenalidomide + Pembrolizumab | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02965885 | Phase I | Pimitespib | A Study of TAS-116 in Patients With Solid Tumors | Completed | USA | ITA | GBR | 0 |
NCT02967133 | Phase II | Nab-paclitaxel + Nivolumab Nivolumab | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT02971501 | Phase II | Osimertinib Bevacizumab + Osimertinib | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | Active, not recruiting | USA | 0 |
NCT02974725 | Phase I | LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Terminated | USA | SWE | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT02978404 | Phase II | Nivolumab | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | Completed | CAN | 0 |
NCT02981108 | Phase Ib/II | Aumolertinib | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | Active, not recruiting | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Completed | USA | POL | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02983578 | Phase II | Danvatirsen + Durvalumab | AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02987998 | Phase I | Cisplatin + Etoposide + Pembrolizumab | Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC | Terminated | USA | 0 |
NCT02991651 | Phase I | Erlotinib + IRX4204 | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC | Suspended | USA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT02994576 | Phase II | Atezolizumab | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS) | Completed | FRA | 0 |
NCT02998528 | Phase III | Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine | A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) | Active, not recruiting | USA | TUR | ROU | ITA | HUN | GRC | FRA | ESP | CAN | BRA | ARG | 4 |
NCT02998567 | Phase I | Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) | Recruiting | GBR | 0 |
NCT03001882 | Phase II | Ipilimumab + Nivolumab | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | NLD | ITA | FRA | ESP | DEU | BEL | 0 |
NCT03003468 | Phase Ib/II | Pembrolizumab + PGG beta-glucan | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | Completed | USA | 0 |
NCT03003962 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | Active, not recruiting | USA | TUR | POL | NLD | HUN | AUS | 6 |
NCT03004105 | Phase II | Durvalumab + Selumetinib | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) | Completed | USA | 0 |
NCT03014648 | Phase II | Atezolizumab | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03023423 | Phase Ib/II | Atezolizumab + Daratumumab Atezolizumab | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) | Completed | USA | POL | HUN | FRA | ESP | 0 |
NCT03023904 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | Withdrawn | 0 | |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT03041181 | Phase II | Docetaxel + Nivolumab Docetaxel | Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab | Terminated | USA | 0 |
NCT03042013 | Phase II | Naquotinib | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | Withdrawn | 0 | |
NCT03048136 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) | Withdrawn | USA | DEU | CAN | ARG | 1 |
NCT03048500 | Phase II | Metformin + Nivolumab | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT03049618 | Phase II | Pembrolizumab + sEphB4-HSA | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | Active, not recruiting | USA | 0 |
NCT03050060 | Phase II | Nelfinavir + Nivolumab | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | Terminated | USA | 0 |
NCT03050554 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03052608 | Phase III | Lorlatinib Crizotinib | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | Active, not recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | ARG | 9 |
NCT03054038 | Phase I | Afatinib + Necitumumab | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | AUS | 0 |
NCT03064854 | Phase I | Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | 3 |
NCT03066206 | Phase II | Poziotinib | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03071757 | Phase I | ABBV-368 ABBV-368 + Nivolumab | A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03082300 | Phase I | Naquotinib | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Terminated | USA | 0 |
NCT03083808 | Phase II | Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium | Phase II Trial of Continuation Therapy in Advanced NSCLC | Completed | USA | 0 |
NCT03086733 | Phase II | Metformin | Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) | Completed | CAN | 0 |
NCT03087448 | Phase Ib/II | Ceritinib + Trametinib | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03087760 | Phase II | Pembrolizumab | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03088930 | Phase II | Crizotinib | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03090737 | Phase II | Nivolumab | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) | Completed | USA | ROU | CAN | 2 |
NCT03093116 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 6 |
NCT03095612 | Phase Ib/II | Docetaxel + Selinexor | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03099174 | Phase I | Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | Completed | USA | FRA | FIN | ESP | DNK | 2 |
NCT03101839 | Phase I | AZD4785 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
NCT03102242 | Phase II | Atezolizumab | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | Completed | USA | 0 |
NCT03102606 | Phase II | Plinabulin Pegfilgrastim | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) | Completed | USA | 3 |
NCT03110978 | Phase II | Nivolumab | Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR | Active, not recruiting | USA | 0 |
NCT03121417 | Phase II | Nivolumab | Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03122717 | Phase I | Gefitinib + Osimertinib | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03123783 | Phase Ib/II | Nivolumab + Sotigalimab | CD40 Agonistic Antibody APX005M in Combination With Nivolumab | Completed | USA | ESP | 0 |
NCT03130764 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | Withdrawn | 0 | |
NCT03131037 | Phase I | AdV-tk + Valacyclovir | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03131206 | Phase Ib/II | Alectinib | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | Terminated | USA | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03137771 | Phase II | Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib | Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | ISR | CAN | 1 |
NCT03138889 | Phase Ib/II | NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DEU | AUS | 0 |
NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03148327 | Phase Ib/II | Durvalumab | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | Active, not recruiting | USA | AUS | 0 |
NCT03156114 | Phase I | Ezabenlimab Miptenalimab | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Completed | USA | POL | GBR | ESP | CAN | 0 |
NCT03157128 | Phase Ib/II | Selpercatinib | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUS | 5 |
NCT03158129 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection | Active, not recruiting | USA | 0 |
NCT03158883 | Phase I | Avelumab | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | Completed | USA | 0 |
NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) | Active, not recruiting | USA | POL | HUN | GBR | DEU | BRA | BGR | 12 |
NCT03164772 | Phase Ib/II | BI 1361849 + Durvalumab + Tremelimumab | Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC | Completed | USA | 0 |
NCT03166254 | Phase I | Pembrolizumab | Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT03166631 | Phase I | BI 891065 + Ezabenlimab BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |
NCT03168464 | Phase Ib/II | Nivolumab | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | Terminated | USA | 0 |
NCT03170206 | Phase Ib/II | Palbociclib Binimetinib Binimetinib + Palbociclib | Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03175224 | Phase Ib/II | Vebreltinib | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) | Recruiting | USA | ITA | HUN | GBR | FRA | FIN | ESP | CAN | AUS | 4 |
NCT03177291 | Phase I | Carboplatin + Pemetrexed Disodium + Pirfenidone Carboplatin + Paclitaxel + Pirfenidone | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | Active, not recruiting | USA | 0 |
NCT03178071 | Expanded access | Lorlatinib | Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations | No longer available | USA | 0 |
NCT03178552 | Phase II | Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 14 |
NCT03179436 | Phase Ib/II | MK-1308 + Pembrolizumab MK-1308 | Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | Completed | USA | SWE | POL | NZL | ITA | ISR | GRC | FRA | ESP | CAN | AUS | 5 |
NCT03181308 | Phase I | Carotuximab + Nivolumab | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | Completed | USA | 0 |
NCT03184571 | Phase II | Bemcentinib + Pembrolizumab | BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC | Completed | USA | NOR | GBR | ESP | 0 |
NCT03191149 | Phase II | Osimertinib | Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations | Recruiting | USA | 0 |
NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Completed | SVK | ROU | POL | LUX | ITA | IRL | GBR | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | ARG | 7 |
NCT03195491 | Phase III | Nivolumab | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) | Completed | 2 | |
NCT03197467 | Phase II | Pembrolizumab | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) | Completed | DEU | 0 |
NCT03202940 | Phase Ib/II | Alectinib + Cobimetinib | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Active, not recruiting | USA | ROU | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 5 |
NCT03215810 | Phase I | Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03217071 | Phase II | Pembrolizumab | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03217669 | Phase I | Epacadostat + Sirolimus | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | Active, not recruiting | USA | 0 |
NCT03220477 | Phase I | Guadecitabine + Mocetinostat + Pembrolizumab | Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | Active, not recruiting | USA | 0 |
NCT03223155 | Phase I | Ipilimumab + Nivolumab | Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03224871 | Phase I | Pembrolizumab Aldesleukin Nivolumab | A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | Completed | USA | 0 |
NCT03225664 | Phase Ib/II | Pembrolizumab Pembrolizumab + Trametinib | BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03228186 | Phase II | Docetaxel + MLN4924 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03228667 | Phase II | Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab | QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy | Active, not recruiting | USA | 0 |
NCT03232892 | Phase II | Trametinib | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03233724 | Phase Ib/II | Pembrolizumab | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Terminated | USA | 0 |
NCT03236935 | Phase I | L-NMMA + Pembrolizumab | Phase Ib of L-NMMA and Pembrolizumab | Active, not recruiting | USA | 0 |
NCT03237377 | Phase II | Durvalumab + Tremelimumab Durvalumab | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03239340 | Phase III | Osimertinib | A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS) | Completed | USA | ITA | ESP | 2 |
NCT03242915 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease | Active, not recruiting | USA | 0 |
NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03256136 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab | A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03257722 | Phase Ib/II | Idelalisib + Pembrolizumab | Pembrolizumab + Idelalisib for Lung Cancer Study | Terminated | USA | 0 |
NCT03260491 | Phase I | Patritumab deruxtecan | HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer | Recruiting | USA | NLD | ESP | 3 |
NCT03262779 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | Completed | USA | 0 |
NCT03265080 | Phase I | ADXS-NEO | Expressing Personalized Tumor Antigens Study | Terminated | USA | 0 |
NCT03268057 | Phase Ib/II | Avelumab + Pepinemab | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03270176 | Phase I | Avelumab + Xevinapant | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | Completed | ROU | POL | CAN | 0 |
NCT03274479 | Phase I | PBF-1129 | PBF-1129 in Patients With NSCLC | Active, not recruiting | USA | 0 |
NCT03275597 | Phase I | Durvalumab + Tremelimumab | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | Terminated | USA | 0 |
NCT03285321 | Phase II | Ipilimumab + Nivolumab Nivolumab | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03285763 | FDA approved | Atezolizumab | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL) | Completed | SWE | SVN | POL | NLD | LVA | LBN | ITA | GRC | GBR | ESP | DNK | BRA | ARG | 11 |
NCT03286296 | Phase I | LZM009 | LZM009 to Treat Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03292133 | Phase II | Gefitinib + Nazartinib | A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03299088 | Phase I | Pembrolizumab + Trametinib | Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | Active, not recruiting | USA | 0 |
NCT03302234 | Phase III | Pembrolizumab Ipilimumab + Pembrolizumab | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) | Completed | USA | TUR | POL | LVA | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 9 |
NCT03302247 | Phase II | Nivolumab Gemcitabine + Nivolumab | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Terminated | USA | 0 |
NCT03307759 | Phase I | Pembrolizumab | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) | Completed | CAN | AUS | 0 |
NCT03308942 | Phase II | Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib | Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | Completed | USA | 0 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03311672 | Phase II | Pembrolizumab | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Withdrawn | 0 | |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Active, not recruiting | USA | 0 |
NCT03317496 | Phase II | Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | Terminated | USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 0 |
NCT03318939 | Phase II | Poziotinib | Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Terminated | USA | NLD | ITA | ISR | FRA | ESP | CAN | BEL | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03322540 | Phase II | Pembrolizumab Epacadostat + Pembrolizumab | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Completed | USA | TUR | POL | ITA | ISR | IRL | GBR | EST | ESP | DNK | CHE | CAN | AUS | 5 |
NCT03322566 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | Completed | USA | TUR | ITA | ISR | IRL | HUN | GBR | ESP | CAN | AUS | 4 |
NCT03325166 | Phase II | Pembrolizumab | Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases | Terminated | USA | 0 |
NCT03326752 | Phase I | DV281 | Phase 1b Dose Escalation and Dose Expansion Trial | Completed | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03333343 | Phase I | LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Active, not recruiting | ITA | DEU | CAN | 3 |
NCT03334617 | Phase II | Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Active, not recruiting | USA | ISR | FRA | ESP | DEU | CAN | AUT | 1 |
NCT03337698 | Phase Ib/II | Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 | A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | DNK | BEL | 0 |
NCT03345810 | Phase II | Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine | Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION) | Completed | DEU | 0 |
NCT03348904 | Phase III | Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT03353675 | Phase II | MVA-MUC1-IL2 vaccine + Nivolumab | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | HUN | FRA | BEL | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03366766 | Phase II | Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium | Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | Completed | USA | 0 |
NCT03367819 | Phase Ib/II | Isatuximab Cemiplimab + Isatuximab | Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies | Terminated | USA | ITA | GBR | FRA | 1 |
NCT03371992 | Phase I | Nivolumab | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) | Unknown status | USA | 0 |
NCT03377023 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03379441 | Phase II | Pembrolizumab | Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) | Unknown status | ITA | 0 |
NCT03380871 | Phase I | Carboplatin + NEO-PV-01 + Pembrolizumab + Pemetrexed Disodium + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | Completed | USA | 0 |
NCT03381274 | Phase Ib/II | AZD4635 + Oleclumab Oleclumab + Osimertinib | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | Active, not recruiting | USA | 2 |
NCT03382899 | Phase II | Pegilodecakin + Pembrolizumab Pembrolizumab | Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) | Terminated | USA | 0 |
NCT03382912 | Phase II | Nivolumab + Pegilodecakin Nivolumab | Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) | Terminated | USA | 0 |
NCT03383302 | Phase Ib/II | Nivolumab | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) | Active, not recruiting | GBR | 0 |
NCT03386929 | Phase Ib/II | Avelumab + Axitinib + Palbociclib | Survival Prolongation by Rationale Innovative Genomics (SPRING) | Terminated | USA | LUX | ISR | ESP | 0 |
NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Terminated | USA | 0 |
NCT03391869 | Phase III | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03392246 | Phase II | Osimertinib + Selumetinib | A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03396497 | Phase I | LYC-55716 + Pembrolizumab | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT03401385 | Phase I | Datopotamab deruxtecan | First-in-human Study of DS-1062a for Advanced Solid Tumors | Recruiting | USA | 1 |
NCT03409458 | Phase Ib/II | Avelumab + Imifoplatin | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) | Completed | USA | CHE | 0 |
NCT03410043 | Phase II | Osimertinib | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | Active, not recruiting | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03417037 | Phase III | Linrodostat + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | TUR | ITA | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 4 |
NCT03417882 | Phase II | GRN-1201 + Pembrolizumab | GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | Terminated | USA | 0 |
NCT03418532 | Phase Ib/II | MP0250 | MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC | Terminated | USA | 0 |
NCT03419559 | Phase II | LN-145 Durvalumab + LN-145 | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03425006 | Phase II | Itacitinib + Pembrolizumab | Pembrolizumab and Itacitinib (INCB039110) for NSCLC | Terminated | USA | 0 |
NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT03425331 | Phase II | Ipilimumab + Nivolumab | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Terminated | USA | 0 |
NCT03425643 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | Active, not recruiting | USA | ROU | POL | LVA | LTU | ITA | IRL | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT03430063 | Phase II | Cemiplimab + Ipilimumab Cemiplimab | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | Terminated | USA | POL | GBR | FRA | ESP | DEU | BEL | 2 |
NCT03433469 | Phase II | Osimertinib | Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery | Active, not recruiting | USA | 0 |
NCT03434418 | Phase II | Osimertinib | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | Completed | USA | 0 |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
NCT03438318 | Phase I | Atezolizumab + Vidutolimod | Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03446417 | Phase I | ZN-e4 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | Completed | USA | 1 |
NCT03446547 | Phase II | Durvalumab | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID) | Recruiting | SWE | NOR | FIN | 0 |
NCT03447769 | Phase III | Canakinumab | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) | Terminated | USA | TUR | SVN | ROU | POL | NOR | LBN | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUT | ARG | 18 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03455556 | Phase Ib/II | Anetumab ravtansine + Atezolizumab | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03455829 | Phase Ib/II | Osimertinib G1T38 + Osimertinib | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03456063 | Phase III | Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | Active, not recruiting | USA | SWE | SVN | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS | 9 |
NCT03456076 | Phase III | Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | AUT | AUS | 12 |
NCT03468985 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03469960 | Phase III | Ipilimumab + Nivolumab | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) | Active, not recruiting | FRA | 0 |
NCT03472560 | Phase II | Avelumab + Axitinib | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | Terminated | USA | POL | ITA | HUN | ESP | 3 |
NCT03473925 | Phase II | Navarixin + Pembrolizumab | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Completed | USA | ISR | CAN | AUS | 1 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03497767 | Phase II | Osimertinib | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN) | Completed | AUS | 1 |
NCT03502330 | Phase I | Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Completed | USA | 0 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Active, not recruiting | USA | POL | GRC | ESP | 2 |
NCT03505710 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01) | Completed | USA | NLD | FRA | ESP | 1 |
NCT03509012 | Phase I | Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) | Active, not recruiting | USA | ESP | 3 |
NCT03515629 | Phase III | Cemiplimab + Ipilimumab Pembrolizumab | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | Terminated | USA | LTU | ITA | 0 |
NCT03515837 | Phase III | Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cisplatin + Pemetrexed Disodium | Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | Completed | USA | SWE | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 6 |
NCT03516214 | Phase I | Nazartinib + Trametinib | EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON) | Completed | ESP | DEU | 0 |
NCT03516981 | Phase II | MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | Active, not recruiting | USA | POL | ITA | IRL | GBR | ESP | CHE | CAN | AUS | 7 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03520686 | Phase III | Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Active, not recruiting | USA | 0 |
NCT03520842 | Phase II | Methotrexate + Regorafenib | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03521154 | Phase III | Osimertinib | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) | Active, not recruiting | USA | TUR | HUN | ESP | BRA | ARG | 11 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Completed | ESP | 0 |
NCT03527108 | Phase II | Nivolumab + Ramucirumab Nivolumab | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Recruiting | USA | 0 |
NCT03535363 | Phase I | Osimertinib | Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | Completed | USA | 0 |
NCT03535740 | Phase II | Brigatinib | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2) | Completed | USA | SWE | NLD | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 5 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539536 | Phase II | Telisotuzumab vedotin | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUS | 6 |
NCT03546361 | Phase I | Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03559049 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03563716 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | ESP | 3 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03567642 | Phase I | Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib | A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | Active, not recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03568656 | Phase Ib/II | Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | 0 |
NCT03573947 | Phase II | Ipilimumab + Nivolumab + Paclitaxel | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) | Completed | USA | 0 |
NCT03574220 | Phase I | Pembrolizumab | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer | Withdrawn | 0 | |
NCT03574649 | Phase II | Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept + Paclitaxel | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT03580694 | Phase I | Cemiplimab + REGN4659 Cemiplimab | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03581487 | Phase Ib/II | Durvalumab + Selumetinib + Tremelimumab | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03583086 | Phase Ib/II | Nivolumab + Vorolanib | H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | Completed | USA | 0 |
NCT03586453 | Phase II | Osimertinib | Osimertinib In EGFR Mutant Lung Cancer | Recruiting | USA | 0 |
NCT03588039 | Phase I | Oraxol + Pembrolizumab | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03589547 | Phase II | Durvalumab | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | Active, not recruiting | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | NLD | ISR | ESP | CAN | AUS | 4 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03596866 | Phase III | Brigatinib Alectinib | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3) | Completed | USA | SWE | ROU | ITA | HRV | GRC | FRA | ESP | DEU | CAN | AUT | ARG | 8 |
NCT03600701 | Phase II | Atezolizumab + Cobimetinib | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Terminated | USA | 0 |
NCT03611738 | Phase I | Ceritinib + Docetaxel | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03625323 | Phase II | Eftilagimod alpha + Pembrolizumab | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) | Active, not recruiting | USA | GBR | ESP | AUS | 1 |
NCT03626545 | Phase III | Canakinumab + Docetaxel Docetaxel | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2) | Terminated | USA | POL | NLD | LBN | ITA | ISR | HUN | GRC | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 8 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03631199 | Phase III | Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) | Active, not recruiting | USA | TUR | SWE | SVK | ROU | POL | NOR | NLD | LBN | ITA | ISL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS | ARG | 15 |
NCT03631706 | Phase II | Bintrafusp alfa Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 6 |
NCT03631784 | Phase II | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799) | Completed | USA | POL | NZL | GBR | FRA | ESP | DEU | AUS | 2 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |
NCT03634241 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules | Recruiting | USA | 0 |
NCT03637491 | Phase II | Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | Terminated | USA | BEL | 1 |
NCT03637803 | Phase I | MRx0518 + Pembrolizumab | MRx0518 and Pembrolizumab Combination Study | Terminated | USA | 0 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
NCT03645928 | Phase II | Lifileucel + Pembrolizumab LN-145 LN-145 + Pembrolizumab | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Recruiting | USA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | 0 |
NCT03647163 | Phase I | Pembrolizumab + VSV-hIFNbeta-NIS | Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC | Recruiting | USA | 0 |
NCT03647488 | Phase II | Capmatinib + Spartalizumab Docetaxel | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | Completed | USA | ISR | FRA | ESP | DEU | BEL | 0 |
NCT03656627 | Phase I | Nivolumab | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | Terminated | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Active, not recruiting | USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG | 2 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03663166 | Phase Ib/II | Cisplatin + Ipilimumab + Pemetrexed Disodium Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT03664024 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) | Completed | USA | ISR | HUN | ESP | CAN | 0 |
NCT03665129 | Phase I | Avdoralimab + Durvalumab | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) | Terminated | USA | FRA | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03666988 | Phase I | GSK3368715 | First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) | Terminated | USA | ESP | CAN | AUS | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03667820 | Phase II | Osimertinib | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | Active, not recruiting | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03674827 | Phase I | PF-06936308 | A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Terminated | USA | 0 |
NCT03679767 | Phase II | Retifanlimab | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | AUT | 0 |
NCT03681483 | Phase I | RO5126766 | RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer | Completed | USA | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03689855 | Phase II | Atezolizumab + Ramucirumab | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1) | Completed | USA | 0 |
NCT03693300 | Phase II | Durvalumab | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Active, not recruiting | USA | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03707938 | Phase I | Brigatinib | Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Completed | USA | NZL | FRA | ESP | DNK | 1 |
NCT03709706 | Phase Ib/II | Letetresgene autoleucel + Pembrolizumab Letetresgene autoleucel | Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab | Terminated | USA | NLD | GBR | ESP | CAN | 0 |
NCT03713944 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03735121 | Phase III | Atezolizumab + rHuPH20 Atezolizumab | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | TUR | POL | NZL | LVA | ITA | HUN | GRC | GBR | FRA | ESP | BRA | ARG | 11 |
NCT03735290 | Phase Ib/II | Pembrolizumab Intuvax + Pembrolizumab | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) | Terminated | USA | 0 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03737994 | Phase II | Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03739710 | Phase Ib/II | Docetaxel Docetaxel + GSK3359609 | Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | SWE | ROU | POL | NLD | ITA | FRA | ESP | DEU | CAN | 2 |
NCT03745222 | Phase III | Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) | Terminated | USA | ROU | POL | NZL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BEL | 7 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03755102 | Phase I | Dacomitinib | A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. | Completed | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Completed | USA | 0 |
NCT03769103 | Phase II | Osimertinib | Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC | Active, not recruiting | CAN | 0 |
NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn | 0 | |
NCT03774732 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG) | Active, not recruiting | FRA | 1 |
NCT03775486 | Phase II | Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) | Active, not recruiting | USA | POL | NLD | HUN | GBR | BEL | 6 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03778229 | Phase II | Osimertinib + Savolitinib | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) | Active, not recruiting | USA | ITA | FRA | ESP | DNK | CAN | BRA | 6 |
NCT03780517 | Phase I | DS-5010 | Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | Completed | USA | FRA | ESP | BEL | 3 |
NCT03784378 | Phase I | RXDX-105 | Continued Access to RXDX-105 | Completed | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03793179 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 1 |
NCT03794544 | Phase II | Durvalumab + Oleclumab Danvatirsen + Durvalumab Durvalumab Durvalumab + Monalizumab | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | Completed | USA | ITA | FRA | ESP | CHE | CAN | 1 |
NCT03797391 | Phase Ib/II | EMB-01 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT03800134 | Phase III | Cisplatin + Durvalumab + Gemcitabine Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Gemcitabine | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | HUN | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | ARG | 13 |
NCT03801902 | Phase I | Durvalumab + Monalizumab Durvalumab | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | Suspended | USA | 0 |
NCT03805841 | Phase II | TH-4000 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) | Terminated | USA | CAN | 1 |
NCT03808558 | Phase II | TVB-2640 | Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | Active, not recruiting | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03810066 | Phase II | Osimertinib | Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | Completed | DEU | 0 |
NCT03810807 | Phase I | Dacomitinib + Osimertinib | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | Active, not recruiting | USA | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03818776 | Phase I | Durvalumab | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | Terminated | USA | 0 |
NCT03819387 | Phase I | NBF-006 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | Completed | USA | 0 |
NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | POL | ESP | BEL | AUT | 4 |
NCT03822351 | Phase II | Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) | Completed | USA | POL | ITA | FRA | ESP | CAN | 3 |
NCT03824327 | Phase I | Papaverine | Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases | Suspended | USA | 0 |
NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Terminated | DEU | 0 |
NCT03829319 | Phase III | Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) | Active, not recruiting | USA | TUR | POL | NZL | ISR | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 5 |
NCT03829332 | Phase III | Pembrolizumab Lenvatinib + Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) | Completed | USA | TUR | POL | ITA | ISR | HUN | FRA | EST | CAN | AUS | 9 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |
NCT03831932 | Phase Ib/II | Osimertinib + Telaglenastat | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03833154 | Phase III | Durvalumab | Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 5 |
NCT03833440 | Phase II | Ceralasertib + Durvalumab Durvalumab + Oleclumab Docetaxel Durvalumab + Monalizumab | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR) | Active, not recruiting | FRA | 0 |
NCT03836352 | Phase II | Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT03838159 | Phase II | Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel | NADIM II: Neo-Adjuvant Immunotherapy (NADIMII) | Active, not recruiting | ESP | 0 |
NCT03840902 | Phase II | Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT03840915 | Phase Ib/II | Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | Completed | USA | FRA | BEL | 0 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 0 |
NCT03845296 | Phase II | Rucaparib | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Active, not recruiting | USA | 0 |
NCT03846310 | Phase I | Carboplatin + Etrumadenant + Pemetrexed Disodium Zimberelimab Carboplatin + Etrumadenant + Pembrolizumab + Pemetrexed Disodium | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Active, not recruiting | USA | 3 |
NCT03847519 | Phase Ib/II | ADXS-503 + Pembrolizumab ADXS-503 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03867175 | Phase III | Pembrolizumab | Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT03891615 | Phase I | Niraparib + Osimertinib | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | Unknown status | USA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ISR | FRA | ESP | AUS | 1 |
NCT03904108 | Phase II | Ramucirumab | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | Terminated | USA | 0 |
NCT03905148 | Phase Ib/II | Lifirafenib + PD-0325901 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | Recruiting | USA | AUS | 0 |
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03915951 | Phase II | Binimetinib + Encorafenib | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | NLD | ITA | ESP | 1 |
NCT03916419 | Phase II | Durvalumab Carboplatin + Paclitaxel | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03916627 | Phase II | Cemiplimab | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC | Recruiting | USA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | ESP | CZE | 2 |
NCT03920839 | Phase I | Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Withdrawn | 0 | |
NCT03924869 | Phase III | Pembrolizumab | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | Active, not recruiting | USA | TUR | ROU | POL | NZL | NOR | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUT | AUS | ARG | 5 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03940703 | Phase II | Osimertinib + Tepotinib Tepotinib | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | BEL | 10 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Completed | USA | NZL | AUS | 4 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT03964727 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | AUS | 2 |
NCT03965468 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS) | Recruiting | NLD | ITA | ESP | CHE | 0 |
NCT03965689 | Phase II | Carboplatin + MLN4924 + Paclitaxel | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03965845 | Phase Ib/II | Palbociclib + Telaglenastat | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Completed | USA | 0 |
NCT03968419 | Phase II | Canakinumab Pembrolizumab Canakinumab + Pembrolizumab | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) | Terminated | USA | TUR | NLD | GRC | FRA | ESP | DEU | CAN | BEL | 3 |
NCT03970746 | Phase Ib/II | PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Active, not recruiting | POL | NLD | FRA | DEU | BEL | 0 |
NCT03971474 | Phase II | Docetaxel + Gemcitabine + Pemetrexed Disodium Docetaxel + Ramucirumab Docetaxel + Gemcitabine Pembrolizumab + Ramucirumab | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | Completed | USA | 0 |
NCT03973333 | Phase Ib/II | Atezolizumab + IMC-C103C IMC-C103C | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Withdrawn | USA | GBR | ESP | 0 |
NCT03974022 | Phase Ib/II | Sunvozertinib | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 6 |
NCT03976518 | Phase II | Atezolizumab | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (CHANCE) | Completed | ITA | 0 |
NCT03977194 | Phase III | Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) | Active, not recruiting | FRA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Completed | USA | 0 |
NCT03989115 | Phase Ib/II | Cobimetinib + RMC-4630 Osimertinib + RMC-4630 | Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC | Completed | USA | 1 |
NCT03989362 | Phase II | Ipilimumab + Vopratelimab | Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) | Completed | USA | CAN | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03991819 | Phase I | Binimetinib + Pembrolizumab | Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer | Recruiting | CAN | 0 |
NCT03993873 | Phase Ib/II | Elzovantinib | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) | Active, not recruiting | USA | FRA | ESP | 1 |
NCT03996473 | Phase Ib/II | Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride | Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | Terminated | USA | NLD | ESP | BEL | 0 |
NCT03999710 | Phase II | Durvalumab | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Terminated | USA | ESP | DEU | BEL | AUS | 4 |
NCT04003246 | Phase III | Durvalumab | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04005144 | Phase I | Binimetinib + Brigatinib | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04006301 | Phase I | JNJ-74699157 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | Completed | USA | FRA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04013542 | Phase I | Ipilimumab + Nivolumab Nivolumab | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | Active, not recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated | USA | POL | ITA | ESP | DEU | 2 |
NCT04025879 | Phase III | Carboplatin + Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 6 |
NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT04032418 | Phase II | Pembrolizumab | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Terminated | USA | ITA | GBR | AUS | 2 |
NCT04032847 | Phase Ib/II | ATL001 + Pembrolizumab ATL001 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Terminated | USA | GBR | FRA | ESP | DEU | 0 |
NCT04036682 | Phase Ib/II | Zipalertinib | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1) | Active, not recruiting | USA | NLD | ITA | ESP | 5 |
NCT04037462 | Phase Ib/II | Dexamethasone | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | Terminated | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04042701 | Phase I | Pembrolizumab + Trastuzumab deruxtecan | DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Completed | USA | NZL | AUS | 3 |
NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
NCT04061590 | Phase II | Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT04062708 | Phase II | Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Completed | USA | GBR | ESP | DEU | CAN | 0 |
NCT04069936 | Phase II | Marrow infiltrating lymphocytes + Pembrolizumab Marrow infiltrating lymphocytes | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs - NSCLC) Alone or in Combination With Pembrolizumab in Advanced Unresectable or Metastatic NSCLC | Terminated | USA | 0 |
NCT04075396 | Phase Ib/II | Lazertinib | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | GBR | ESP | 0 |
NCT04077099 | Phase Ib/II | REGN5093 | REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | 1 |
NCT04077463 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT04081688 | Phase I | Atezolizumab + Varlilumab | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | Active, not recruiting | USA | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 4 |
NCT04092283 | Phase III | Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 1 |
NCT04092673 | Phase Ib/II | Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) | Recruiting | USA | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Active, not recruiting | FRA | 0 |
NCT04111705 | Phase II | Lorlatinib | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) | Active, not recruiting | FRA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04120454 | Phase II | Pembrolizumab + Ramucirumab | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04123379 | Phase II | BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT04127110 | Phase II | Lorlatinib | Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE) | Active, not recruiting | NOR | NLD | GBR | FRA | ESP | BEL | 1 |
NCT04129502 | Phase III | Mobocertinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Active, not recruiting | USA | TUR | SWE | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 9 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04131543 | Phase II | Cabozantinib | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | Unknown status | ITA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04139317 | Phase II | Capmatinib + Pembrolizumab Pembrolizumab | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50% | Terminated | NLD | ITA | GRC | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 6 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | TUR | ISR | GBR | ESP | DNK | 5 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04141644 | Phase I | Ipilimumab + Osimertinib | Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi) | Active, not recruiting | USA | 0 |
NCT04143789 | Phase Ib/II | AP-002 | Evaluation of AP-002 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT04146571 | Expanded access | Ensartinib | Expanded Access to Ensartinib for Participants With ALK+ NSCLC | Available | USA | 0 |
NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
NCT04151563 | Phase Ib/II | Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab | A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Withdrawn | USA | ROU | POL | NOR | NLD | GRC | DNK | BEL | ARG | 1 |
NCT04157517 | Phase I | TAK-573 | A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study | Completed | USA | AUS | 0 |
NCT04158700 | Phase Ib/II | LY3200882 + Pembrolizumab | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Withdrawn | USA | FRA | ESP | 0 |
NCT04165070 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + Vibostolimab Carboplatin + Paclitaxel + Pembrolizumab + Vibostolimab | Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A) | Recruiting | USA | POL | ITA | ISR | HUN | ESP | 1 |
NCT04165083 | Phase II | MK-4830 + Pembrolizumab | KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) | Active, not recruiting | USA | POL | ITA | ISR | HUN | ESP | 1 |
NCT04165096 | Phase II | MK-5890 + Pembrolizumab | Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C) | Active, not recruiting | USA | POL | ITA | ISR | HUN | ESP | 1 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT04166487 | Phase II | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium | Plasma-Adapted First-Line Pembro In NSCLC | Active, not recruiting | USA | 0 |
NCT04173338 | Phase I | Cabozantinib + Pemetrexed Disodium | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | Terminated | USA | 0 |
NCT04173507 | Phase II | Avelumab + Talazoparib | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | Completed | USA | 0 |
NCT04185883 | Phase Ib/II | Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Recruiting | USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS | 3 |
NCT04189614 | Phase I | Cofetuzumab pelidotin | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer | Active, not recruiting | USA | ISR | ESP | 3 |
NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | Recruiting | USA | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04202809 | Phase II | Durvalumab | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) | Recruiting | DEU | 0 |
NCT04205552 | Phase II | Nivolumab + Relatlimab Nivolumab | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict) | Recruiting | NLD | DEU | BEL | 0 |
NCT04205812 | Phase III | Retifanlimab Pemetrexed Disodium Carboplatin + Nab-paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Nab-paclitaxel + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Retifanlimab Carboplatin + Paclitaxel | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) | Active, not recruiting | USA | TUR | ROU | POL | HUN | CZE | BRA | BGR | 9 |
NCT04214262 | Phase III | Atezolizumab | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04216316 | Phase Ib/II | Avelumab + Carboplatin + Gemcitabine Avelumab + Berzosertib + Carboplatin + Gemcitabine | Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04219254 | Phase Ib/II | BI-1206 + Pembrolizumab | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | SWE | 0 |
NCT04222972 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) | Active, not recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUS | ARG | 6 |
NCT04223596 | Phase II | Brigatinib | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) | Active, not recruiting | ESP | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
NCT04227028 | Phase I | Bevacizumab + Brigatinib | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | Active, not recruiting | USA | 0 |
NCT04233021 | Phase II | Osimertinib | Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) | Active, not recruiting | FRA | 0 |
NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Terminated | USA | 0 |
NCT04245514 | Phase II | Durvalumab | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | Recruiting | DEU | CHE | 0 |
NCT04249362 | Phase II | Durvalumab | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) | Active, not recruiting | USA | POL | ITA | FRA | ESP | 1 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | AUS | 0 |
NCT04250246 | Phase II | Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) | Not yet recruiting | ITA | 0 |
NCT04250545 | Phase I | Sapanisertib + Telaglenastat | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04253964 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | Recruiting | USA | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04256707 | Phase Ib/II | Pembrolizumab + Selinexor Docetaxel + Selinexor Fluorouracil + Irinotecan + Leucovorin + Selinexor Selinexor | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT) | Recruiting | ISR | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04262375 | Phase II | Durvalumab + Oleclumab | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) | Withdrawn | CAN | 0 |
NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
NCT04262869 | Phase II | Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | Withdrawn | 0 | |
NCT04263051 | Phase II | Nivolumab + UCPVax | Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax) | Active, not recruiting | FRA | 0 |
NCT04267237 | Phase II | Atezolizumab + Autogene cevumeran Atezolizumab | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT04267848 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial | Recruiting | USA | 1 |
NCT04268550 | Phase II | Selpercatinib | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | Active, not recruiting | USA | 0 |
NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Recruiting | USA | 2 |
NCT04270864 | Phase I | IMO-2125 + Ipilimumab + Nivolumab | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) | Terminated | FRA | 0 |
NCT04272203 | Phase I | ABBV-184 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | Terminated | USA | ISR | GBR | FRA | 1 |
NCT04274907 | Phase I | Pembrolizumab + Venetoclax Pembrolizumab | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression | Terminated | USA | 0 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04285671 | Phase Ib/II | Necitumumab + Osimertinib + Trastuzumab | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04291105 | Phase II | Cemiplimab + VSV-hIFNbeta-NIS | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Recruiting | USA | BRA | 0 |
NCT04292119 | Phase Ib/II | Binimetinib + Lorlatinib Crizotinib + Lorlatinib | Lorlatinib Combinations in Lung Cancer | Unknown status | USA | 0 |
NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Active, not recruiting | USA | 0 |
NCT04294810 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) | Active, not recruiting | USA | TUR | POL | NLD | ITA | HUN | GRC | ESP | DNK | DEU | CHE | BRA | AUT | AUS | 10 |
NCT04297605 | Phase I | Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | Recruiting | USA | 0 |
NCT04302025 | Phase II | Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04303780 | Phase III | Sotorasib Docetaxel | Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | Active, not recruiting | USA | SWE | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | 5 |
NCT04310007 | Phase II | Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04310020 | Phase II | Atezolizumab | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Recruiting | USA | 0 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Terminated | USA | NZL | ITA | 0 |
NCT04314089 | Phase I | GT103 | Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) | Active, not recruiting | USA | 0 |
NCT04317534 | Phase II | Pembrolizumab | Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Recruiting | USA | 0 |
NCT04318938 | Phase II | Brigatinib | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | Active, not recruiting | DEU | 0 |
NCT04323436 | Phase II | Capmatinib + Spartalizumab Capmatinib | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 2 |
NCT04330664 | Phase Ib/II | Adagrasib + TNO155 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Active, not recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04335292 | Phase II | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Osimertinib | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT) | Recruiting | CAN | 0 |
NCT04340882 | Phase II | Docetaxel + Pembrolizumab + Ramucirumab | Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (TaxRamPem) | Recruiting | USA | 0 |
NCT04348292 | Phase I | Durvalumab + Sirolimus | Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04349267 | Phase Ib/II | BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Terminated | USA | CAN | 1 |
NCT04351256 | Phase II | Durvalumab | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) | Recruiting | DEU | 0 |
NCT04362072 | FDA approved | Lorlatinib | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | Completed | USA | POL | ITA | GBR | ESP | CHE | 1 |
NCT04364048 | Phase II | Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04364620 | Phase II | Docetaxel + Sotevtamab | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT04367311 | Phase II | Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Docetaxel | Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | Recruiting | USA | 0 |
NCT04372927 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | Terminated | USA | 0 |
NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG | 9 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04383938 | Phase Ib/II | APR-246 + Pembrolizumab | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Completed | USA | 0 |
NCT04385368 | Phase III | Durvalumab | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 11 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04396535 | Phase II | Bintrafusp alfa + Docetaxel Docetaxel | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04410796 | Phase II | Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Recruiting | USA | 0 |
NCT04413201 | FDA approved | Afatinib + Osimertinib Osimertinib | AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC | Active, not recruiting | DEU | 0 |
NCT04418167 | Phase I | JSI-1187 Dabrafenib + JSI-1187 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Suspended | USA | 0 |
NCT04419532 | Phase I | DS-1055a | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04427072 | Phase III | Docetaxel Capmatinib | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III) | Completed | NLD | ITA | FRA | ESP | DEU | BRA | BEL | 3 |
NCT04432207 | Phase I | IMU-201 Atezolizumab + IMU-201 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | Active, not recruiting | USA | AUS | 0 |
NCT04440735 | Phase Ib/II | Atezolizumab + DSP107 DSP107 | A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04441138 | Phase II | Durvalumab | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) | Suspended | USA | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04444427 | Phase Ib/II | GLR2007 | Evaluation of GLR2007 for Advanced Solid Tumors | Completed | USA | 0 |
NCT04449874 | Phase I | Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Recruiting | USA | POL | NZL | NOR | NLD | ITA | ISR | HUN | GBR | ESP | DEU | CHE | CAN | BRA | BEL | AUS | 3 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04452214 | Phase I | Nidanilimab + Pembrolizumab | A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors | Completed | USA | 0 |
NCT04467723 | Phase Ib/II | Atezolizumab + Pirfenidone | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | Recruiting | USA | 0 |
NCT04467801 | Phase II | Ipatasertib Docetaxel + Ipatasertib | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung) | Recruiting | USA | 0 |
NCT04471415 | Phase Ib/II | DRP-104 Atezolizumab + DRP-104 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | Terminated | USA | ESP | DEU | 2 |
NCT04471428 | Phase III | Docetaxel Atezolizumab + Cabozantinib | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01) | Active, not recruiting | USA | POL | ITA | GRC | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 4 |
NCT04475939 | Phase III | Pembrolizumab Niraparib + Pembrolizumab | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BGR | BEL | AUS | ARG | 6 |
NCT04479306 | Phase I | Osimertinib + Sapanisertib Alisertib + Osimertinib | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT04484142 | Phase II | Datopotamab deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | 3 |
NCT04486833 | Phase Ib/II | Osimertinib + Quaratusugene Ozeplasmid Carboplatin Cisplatin | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1) | Recruiting | USA | 0 |
NCT04487080 | Phase III | Amivantamab-vmjw + Lazertinib Lazertinib Osimertinib | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 12 |
NCT04491084 | Phase Ib/II | CDX-1140 + CDX-301 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (FLT3) | Terminated | USA | 0 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04495153 | Phase II | AdV-tk | GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Active, not recruiting | USA | 0 |
NCT04499053 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab | Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |
NCT04511845 | Phase I | SPYK04 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Active, not recruiting | USA | 1 |
NCT04512430 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | Terminated | ESP | 0 |
NCT04513925 | Phase III | Atezolizumab + Tiragolumab Durvalumab | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) | Active, not recruiting | USA | TUR | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04526509 | Phase I | Cyclophosphamide + Fludarabine GSK3901961 GSK3845097 | Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Terminated | USA | SWE | NLD | DEU | CAN | AUS | 0 |
NCT04526691 | Phase I | Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | Active, not recruiting | USA | ITA | ESP | 2 |
NCT04526782 | Phase II | Docetaxel Binimetinib + Encorafenib | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | Recruiting | FRA | 0 |
NCT04533451 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04541407 | Phase I | Osimertinib + Temozolomide Lorlatinib + Temozolomide | Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease | Completed | USA | 0 |
NCT04543188 | Phase I | Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | Terminated | USA | ISR | CAN | 0 |
NCT04547504 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) | Active, not recruiting | FRA | 0 |
NCT04550104 | Phase I | AZD1390 Olaparib | A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE) | Recruiting | GBR | 0 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |
NCT04560686 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04564157 | Phase III | Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) | Active, not recruiting | ESP | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04585035 | Phase Ib/II | D-1553 | Study to Evaluate D-1553 in Subjects With Solid Tumors | Active, not recruiting | USA | AUS | 2 |
NCT04585477 | Phase II | Durvalumab | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Recruiting | USA | 0 |
NCT04585490 | Phase III | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Recruiting | USA | 0 |
NCT04585815 | Phase Ib/II | Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | Active, not recruiting | USA | GBR | BEL | AUS | 1 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04597671 | Phase III | Durvalumab | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28) | Recruiting | NLD | 0 |
NCT04601402 | Phase I | Avelumab + GEN-001 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | Completed | USA | 0 |
NCT04603807 | Phase III | Entrectinib Crizotinib | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | Recruiting | TUR | SWE | SVK | ROU | NLD | LBN | ITA | HRV | GRC | FRA | ESP | DEU | BRA | 6 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04606446 | Phase I | PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) | Recruiting | USA | AUS | 3 |
NCT04606771 | Phase II | Savolitinib Osimertinib + Savolitinib | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC) | Active, not recruiting | USA | ARG | 4 |
NCT04609566 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04612751 | Phase I | Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) | Recruiting | USA | TUR | POL | ITA | FRA | ESP | BEL | 3 |
NCT04613596 | Phase II | Adagrasib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib Carboplatin + Pembrolizumab + Pemetrexed Disodium | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 17 |
NCT04614103 | Phase II | LN-145 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Recruiting | USA | NLD | DEU | CHE | CAN | 0 |
NCT04619004 | Phase II | Patritumab deruxtecan | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BGR | BEL | AUT | AUS | 5 |
NCT04620330 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202) | Completed | USA | ITA | FRA | ESP | DEU | 0 |
NCT04621188 | Phase II | Lorlatinib | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | Recruiting | FRA | 0 |
NCT04622007 | Phase II | Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium + Tomivosertib Pembrolizumab Pembrolizumab + Tomivosertib | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (KICKSTART) | Active, not recruiting | USA | AUS | 1 |
NCT04623775 | Phase II | Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 3 |
NCT04625647 | Phase II | Sotorasib | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Recruiting | USA | 1 |
NCT04625699 | Phase II | Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | Withdrawn | 0 | |
NCT04634110 | Phase II | Brigatinib | Brigatinib Before Brain Irradiation Trial (B3i Trial) | Terminated | USA | 0 |
NCT04638582 | Phase II | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | Recruiting | CAN | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04642469 | Phase III | Durvalumab | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) | Completed | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT04644237 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 3 |
NCT04648033 | Phase I | Atovaquone | Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (ARCADIAN) | Completed | GBR | 0 |
NCT04655976 | Phase II | Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 6 |
NCT04656652 | Phase III | Docetaxel Datopotamab deruxtecan | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | Active, not recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04667234 | Expanded access | Sotorasib | Expanded Access of Sotorasib | No longer available | USA | ISR | BRA | ARG | 2 |
NCT04676477 | Phase I | Patritumab deruxtecan Osimertinib + Patritumab deruxtecan | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | Active, not recruiting | USA | 3 |
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
NCT04681131 | Phase II | Mecbotamab Vedotin Mecbotamab Vedotin + unspecified PD-1 antibody | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Active, not recruiting | USA | POL | ITA | GRC | ESP | 2 |
NCT04683250 | Phase Ib/II | Vepafestinib | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) | Recruiting | USA | 1 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Terminated | USA | CAN | 0 |
NCT04685135 | Phase III | Docetaxel Adagrasib | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 6 |
NCT04699123 | Phase II | NC318 + Pembrolizumab NC318 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04701476 | Phase II | Pembrolizumab + Tirapazamine | TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Recruiting | USA | 1 |
NCT04716946 | Phase II | Durvalumab | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04721015 | Phase I | ABBV-637 + Docetaxel ABBV-637 + Osimertinib ABBV-637 | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | Active, not recruiting | USA | ISR | FRA | ESP | AUS | 3 |
NCT04725188 | Phase II | Docetaxel Docetaxel + MK-7684A MK-7684A | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | Completed | USA | POL | ITA | ISR | FRA | FIN | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 5 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04735068 | Phase II | Binimetinib + Hydroxychloroquine | Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04736173 | Phase III | Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab | Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10) | Active, not recruiting | USA | TUR | GRC | 9 |
NCT04738487 | Phase III | Pembrolizumab MK-7684A | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | Active, not recruiting | USA | TUR | ROU | HUN | CAN | BRA | 17 |
NCT04739358 | Phase Ib/II | Tepotinib | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | Terminated | USA | 0 |
NCT04743505 | Phase Ib/II | Osimertinib + Vebreltinib | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | BRA | AUS | ARG | 9 |
NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Recruiting | USA | 0 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT04752826 | Phase Ib/II | BI-1808 + Pembrolizumab BI-1808 | BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) | Recruiting | USA | SWE | HUN | GBR | DNK | 1 |
NCT04762199 | Phase I | MRX-2843 + Osimertinib | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04765709 | Phase II | Cisplatin + Dulanermin + Vinorelbine Carboplatin + Durvalumab + Vinorelbine Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE) | Active, not recruiting | ITA | FRA | ESP | 0 |
NCT04772989 | Phase I | AB308 + Zimberelimab | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) | Active, not recruiting | USA | POL | ESP | 0 |
NCT04776447 | Phase II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) | Active, not recruiting | ESP | 0 |
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | ISR | FRA | ESP | 2 |
NCT04780217 | Phase Ib/II | T3011 Pembrolizumab + T3011 | A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT04780568 | Phase I | BC2059 + Osimertinib | Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04786093 | Phase II | Durvalumab | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Recruiting | USA | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04789668 | Phase Ib/II | Bintrafusp alfa + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Completed | USA | 0 |
NCT04791839 | Phase II | AB154 + Etrumadenant + Zimberelimab | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04793815 | FDA approved | Pembrolizumab | Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) | Completed | CAN | 0 |
NCT04795713 | Phase I | MT-6402 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Terminated | USA | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Terminated | ESP | 0 |
NCT04811001 | Phase II | Dacomitinib Osimertinib | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) | Recruiting | ITA | 0 |
NCT04816214 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Capmatinib + Osimertinib | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E) | Terminated | 3 | |
NCT04819100 | Phase III | Selpercatinib | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 11 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04822298 | Phase I | AMG 160 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | AUT | AUS | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
NCT04830202 | Expanded access | Telisotuzumab vedotin | Expanded Access to Telisotuzumab Vedotin | Available | USA | ISR | DEU | AUS | 1 |
NCT04832854 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | Active, not recruiting | USA | ESP | CHE | AUS | 1 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04837716 | Phase I | Bevacizumab + Carboplatin + Ensartinib + Pemetrexed Disodium | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | USA | GBR | AUS | 1 |
NCT04849273 | Phase Ib/II | TPX-0131 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | Terminated | USA | AUS | 1 |
NCT04856176 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim | A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | Recruiting | USA | 0 |
NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Active, not recruiting | USA | NLD | GBR | FRA | ESP | CAN | 4 |
NCT04863248 | Phase II | Docetaxel + Trilaciclib Docetaxel | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | Terminated | USA | 0 |
NCT04866017 | Phase III | Durvalumab BGBA1217 + Tislelizumab Tislelizumab | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Terminated | USA | ESP | AUS | 2 |
NCT04868877 | Phase Ib/II | MCLA-129 + Osimertinib MCLA-129 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | BEL | 2 |
NCT04870112 | Phase Ib/II | Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) | Terminated | USA | NZL | ESP | 1 |
NCT04875585 | Phase II | Lenvatinib + Pembrolizumab | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1) | Recruiting | AUT | 0 |
NCT04879849 | Phase I | Pembrolizumab + TAK-676 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | Completed | USA | 0 |
NCT04880863 | Phase II | Docetaxel + Naptumomab estafenatox + Obinutuzumab | Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1) | Completed | USA | 0 |
NCT04884282 | Phase II | Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED) | Recruiting | ITA | FRA | ESP | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04892472 | Phase II | Pembrolizumab | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36) | Recruiting | USA | 0 |
NCT04892953 | Phase II | Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Recruiting | USA | 0 |
NCT04895579 | Phase I | Copanlisib + Durvalumab | Lung Cancer With Copanlisib and Durvalumab (LCD) | Active, not recruiting | USA | 0 |
NCT04898543 | Phase I | m-ceNK cells + Nogapendekin alfa inbakicept | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04903873 | Phase Ib/II | EU101 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04905316 | Phase II | Canakinumab + Durvalumab | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (CHORUS) | Active, not recruiting | USA | 0 |
NCT04908956 | Phase II | Osimertinib | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO) | Terminated | SWE | POL | NLD | ITA | ESP | CHE | 2 |
NCT04914897 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | Terminated | USA | POL | ITA | FRA | ESP | AUS | ARG | 4 |
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT04919369 | Phase I | Atezolizumab + Tretinoin | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04919811 | Phase II | Taletrectinib | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) | Recruiting | USA | POL | ITA | FRA | ESP | CAN | 3 |
NCT04921358 | Phase III | Docetaxel Sitravatinib + Tislelizumab | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Terminated | AUS | 1 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04926831 | Phase II | Capmatinib | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N) | Completed | USA | 0 |
NCT04928846 | Phase III | Telisotuzumab vedotin Docetaxel | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 8 |
NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
NCT04933695 | Phase II | Sotorasib | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201) | Active, not recruiting | USA | TUR | SWE | NLD | ITA | FRA | ESP | DNK | DEU | BEL | 0 |
NCT04933903 | Phase II | Ipilimumab + Nivolumab | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | Recruiting | USA | 0 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
NCT04940299 | Phase II | Ipilimumab + Nivolumab + Tocilizumab | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | Active, not recruiting | USA | 0 |
NCT04940325 | Phase II | Datopotamab deruxtecan | Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01) | Active, not recruiting | FRA | 0 |
NCT04940637 | Phase II | Dostarlimab-gxly + Niraparib | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001) | Recruiting | ITA | 0 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04944173 | Phase II | Durvalumab | A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer (SCION) | Withdrawn | CAN | 0 |
NCT04957290 | Phase Ib/II | NOX66 | A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | Terminated | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04959981 | Phase Ib/II | ERAS-007 + Osimertinib ERAS-601 + Sotorasib ERAS-007 + Sotorasib | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2) | Completed | USA | 0 |
NCT04964960 | Phase II | Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab | Pembro+Chemo in Brain Mets | Terminated | USA | 0 |
NCT04965090 | Phase II | Amivantamab-vmjw + Lazertinib | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT04965818 | Phase Ib/II | Binimetinib + Futibatinib | Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | Terminated | USA | 0 |
NCT04966663 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Gemcitabine + Nivolumab | Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT) | Recruiting | CAN | 0 |
NCT04966676 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) | Active, not recruiting | CAN | 0 |
NCT04969315 | Phase Ib/II | TT-10 | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | Active, not recruiting | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT04975256 | Phase I | Adagrasib + BI 1701963 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Completed | USA | 0 |
NCT04982224 | Phase Ib/II | REGN5093-M114 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | Recruiting | USA | 0 |
NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Active, not recruiting | USA | FRA | 0 |
NCT04984811 | Phase II | Atezolizumab + NT-I7 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | Active, not recruiting | USA | 0 |
NCT04989283 | Phase II | Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT04999202 | Phase I | BAY2416964 + Pembrolizumab BAY2416964 | A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults | Active, not recruiting | USA | ITA | GBR | 1 |
NCT05000710 | Phase II | Durvalumab Durvalumab + Tremelimumab Tremelimumab | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung) | Recruiting | ISR | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Completed | USA | TUR | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS | ARG | 1 |
NCT05005403 | Phase I | ABBV-514 + Budigalimab ABBV-514 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab | Recruiting | USA | ISR | 3 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05007769 | Phase II | Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN) | Withdrawn | 0 | |
NCT05012254 | Phase II | Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) | Active, not recruiting | ESP | 0 |
NCT05013450 | Phase Ib/II | Dupilumab + unspecified PD-L1 antibody Dupilumab + unspecified PD-1 antibody | Dupilumab_Metastatic NSCLC | Recruiting | USA | 0 |
NCT05014815 | Phase II | BGBA1217 + Tislelizumab Tislelizumab | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | Completed | USA | FRA | ESP | AUT | AUS | 2 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05054725 | Phase II | RMC-4630 + Sotorasib | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Unknown status | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05061017 | Phase II | Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | Completed | USA | 0 |
NCT05061537 | Phase I | PF-06801591 + PF-07263689 PF-07263689 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | USA | 0 |
NCT05061550 | Phase II | Durvalumab + Monalizumab Durvalumab + Oleclumab | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | Recruiting | USA | TUR | ITA | IRL | HUN | FRA | ESP | CAN | BEL | 3 |
NCT05062980 | Phase Ib/II | Pembrolizumab + Quaratusugene Ozeplasmid Docetaxel + Ramucirumab | Reqorsa (Quaratusugene Ozeplasmid) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2) | Active, not recruiting | USA | 0 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |
NCT05068024 | Phase Ib/II | FWD1509 MsOH | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509) | Recruiting | USA | 0 |
NCT05068102 | Phase I | BI 770371 + Ezabenlimab Effi-DEM + Ezabenlimab | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | Recruiting | NLD | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05074810 | Phase Ib/II | RO5126766 + Sotorasib Defactinib + RO5126766 + Sotorasib | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203) | Recruiting | USA | NLD | GBR | FRA | ESP | BEL | 0 |
NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Unknown status | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Active, not recruiting | USA | GBR | ESP | 0 |
NCT05082610 | Phase I | HMBD-002 HMBD-002 + Pembrolizumab | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | 0 |
NCT05083481 | Phase Ib/II | ASP1570 | A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05084859 | Phase I | Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | Terminated | USA | AUS | 0 |
NCT05085028 | Phase III | Pembrolizumab | A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (REFINE-Lung) | Recruiting | GBR | 0 |
NCT05089734 | Phase III | Docetaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy (EVOKE-01) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 4 |
NCT05089916 | Phase II | Osimertinib | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) | Recruiting | DEU | 0 |
NCT05091528 | Phase Ib/II | SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Terminated | USA | 0 |
NCT05094336 | Phase Ib/II | AMG193 AMG193 + Docetaxel | A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (MTAP) | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05096663 | Phase II | Dexamethasone + Docetaxel + Gemcitabine + Pemetrexed Disodium + Ramucirumab Nogapendekin alfa inbakicept + Pembrolizumab | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | Active, not recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05099172 | Phase I | BAY2927088 | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | Recruiting | USA | POL | NLD | ITA | ISR | FRA | ESP | BRA | BEL | 7 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05104515 | Phase I | OVM-200 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | Recruiting | GBR | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05109442 | Phase Ib/II | AFM24 + Atezolizumab | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Recruiting | USA | POL | GBR | ESP | 1 |
NCT05116891 | Phase Ib/II | Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | Completed | FRA | ESP | 0 |
NCT05117242 | Phase II | GEN1046 + Pembrolizumab GEN1046 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | 1 |
NCT05118789 | Phase Ib/II | NUV-520 | A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05119933 | Phase Ib/II | YL-15293 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | Unknown status | USA | 0 |
NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Withdrawn | 0 | |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT05128630 | Phase II | Durvalumab | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS) | Recruiting | ITA | 0 |
NCT05132075 | Phase III | JDQ443 Docetaxel | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) | Active, not recruiting | USA | TUR | SVN | ROU | LBN | ITA | ISL | HUN | GRC | FIN | ESP | CAN | AUS | ARG | 12 |
NCT05136846 | Phase I | Carboplatin + Durvalumab + Paclitaxel + Papaverine | Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05141357 | Phase II | Chidamide + Pembrolizumab | A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000) | Terminated | USA | 0 |
NCT05142189 | Phase I | BNT116 + Cemiplimab BNT116 + Docetaxel BNT116 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1) | Recruiting | USA | TUR | POL | HUN | GBR | ESP | DEU | 0 |
NCT05144529 | Phase II | Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101) | Recruiting | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05144997 | FDA approved | Lorlatinib | Lorlatinib Continuation Study | Active, not recruiting | USA | FRA | ESP | 5 |
NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Terminated | USA | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05166616 | Phase I | Minnelide + Osimertinib | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05168566 | Phase II | Sutetinib maleate | Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 1 |
NCT05171062 | Phase I | FP-1305 + Pembrolizumab | Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT05171777 | Phase II | Atezolizumab | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | Active, not recruiting | USA | POL | LVA | ITA | FIN | ESP | CAN | BRA | ARG | 3 |
NCT05180422 | Phase Ib/II | Bevacizumab-awwb + Sotorasib | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | Withdrawn | USA | 0 |
NCT05186974 | Phase II | Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Pembrolizumab + Sacituzumab govitecan-hziy Cisplatin + Pembrolizumab + Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations (EVOKE-02) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT05200481 | Phase II | Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | Active, not recruiting | FRA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT05208944 | Phase II | Cemiplimab + THIO | A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab in Subjects With Advanced NSCLC | Recruiting | POL | HUN | BGR | AUS | 0 |
NCT05211895 | Phase III | Durvalumab AB154 + Durvalumab | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) | Recruiting | USA | TUR | ROU | POL | NOR | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | 11 |
NCT05212922 | Phase II | Toripalimab-tpzi + YH001 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001) | Withdrawn | AUT | AUS | 3 |
NCT05215340 | Phase III | Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05221840 | Phase III | Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 11 |
NCT05226598 | Phase III | Carboplatin + MK-7684A + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + MK-7684A + Pemetrexed Disodium Carboplatin + MK-7684A + Nab-paclitaxel Carboplatin + MK-7684A + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | Active, not recruiting | USA | TUR | POL | ISR | GBR | FRA | ESP | DEU | BRA | AUT | ARG | 8 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | AUS | 0 |
NCT05229614 | Phase II | Pembrolizumab | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC) | Recruiting | ITA | DEU | 0 |
NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Terminated | USA | SWE | GBR | ESP | CAN | 0 |
NCT05233436 | Phase I | PF-07265028 PF-06801591 + PF-07265028 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Terminated | USA | 1 |
NCT05234307 | Phase I | Nivolumab + PBF-1129 | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05241873 | Phase Ib/II | BLU-451 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Active, not recruiting | USA | CAN | 3 |
NCT05253807 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210) | Completed | USA | ITA | FRA | ESP | DEU | 0 |
NCT05255302 | Phase II | Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL) | Recruiting | FRA | 0 |
NCT05256290 | Phase I | BDTX-1535 BDTX-1535 + Temozolomide | Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Recruiting | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Recruiting | FRA | 0 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Active, not recruiting | USA | 0 |
NCT05261399 | Phase III | Osimertinib + Savolitinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 12 |
NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | Recruiting | USA | GBR | ESP | 1 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05265650 | Phase Ib/II | BO-112 + Nivolumab | Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia) | Unknown status | ESP | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05274451 | Phase I | LYL797 | A Study to Investigate LYL797 in Adults with Solid Tumors | Active, not recruiting | USA | 0 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05275478 | Phase Ib/II | TNG908 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT05275868 | Phase I | MGY825 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | CHE | 2 |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05281406 | Phase II | Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium | Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | Recruiting | DEU | 0 |
NCT05298176 | Phase II | Afatinib Afatinib + Carboplatin + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib | Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION) | Recruiting | NLD | 0 |
NCT05298423 | Phase III | Cisplatin + MK-7684A + Pemetrexed Disodium Cisplatin + Durvalumab + Paclitaxel Carboplatin + MK-7684A + Paclitaxel Cisplatin + Etoposide + MK-7684A Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Etoposide | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) | Recruiting | USA | TUR | ROU | ITA | ISR | GRC | ESP | DEU | CZE | BRA | AUS | 13 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05299125 | Phase II | Amivantamab-vmjw + Lazertinib + Pemetrexed Disodium | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1) | Recruiting | BRA | 0 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05311709 | Phase II | Sotorasib | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM) | Recruiting | NOR | 0 |
NCT05313009 | Phase Ib/II | Sotorasib + TH-4000 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Terminated | USA | 0 |
NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Terminated | USA | CHE | AUS | 0 |
NCT05317858 | Phase III | Pembrolizumab | Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Recruiting | USA | CAN | 1 |
NCT05332574 | Phase Ib/II | GB263T | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | Recruiting | AUS | 0 |
NCT05334329 | Phase I | Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells | Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | Active, not recruiting | USA | 0 |
NCT05340309 | Phase II | Atezolizumab + rHuPH20 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05344209 | Phase II | Atezolizumab Pembrolizumab Cemiplimab Cemiplimab + Sargramostim + UV1 Telomerase peptide vaccine Pembrolizumab + Sargramostim + UV1 Telomerase peptide vaccine Atezolizumab + Sargramostim + UV1 Telomerase peptide vaccine | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC) | Recruiting | NOR | 0 |
NCT05358249 | Phase Ib/II | JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
NCT05358691 | Phase I | Durvalumab + E7046 | A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants | Not yet recruiting | USA | 0 |
NCT05361174 | Phase Ib/II | IOV-4001 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Recruiting | USA | 0 |
NCT05364073 | Phase I | Furmonertinib | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05364645 | Phase II | Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT05374538 | Phase I | VIC-1911 Sotorasib + VIC-1911 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT05375084 | Phase I | BBP-398 + Nivolumab | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | Recruiting | USA | 0 |
NCT05375994 | Phase Ib/II | Adagrasib + RO5126766 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204) | Active, not recruiting | USA | 0 |
NCT05378763 | Phase III | Poziotinib Docetaxel | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE) | Suspended | USA | 0 |
NCT05383001 | Phase II | Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) | Withdrawn | DEU | 0 |
NCT05384626 | Phase Ib/II | NVL-655 | A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 4 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |
NCT05388669 | Phase III | Amivantamab-vmjw + Lazertinib | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3) | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 7 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT05393635 | Phase I | ITIL-168 + Pembrolizumab | ITIL-168 in Advanced Solid Tumors (DELTA-2) | Withdrawn | 0 | |
NCT05394831 | Phase Ib/II | JIN-A02 | A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | Recruiting | USA | 2 |
NCT05397171 | Phase Ib/II | AZD8853 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | Terminated | USA | CAN | 0 |
NCT05398094 | Phase II | Sotorasib | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung) | Recruiting | ESP | 0 |
NCT05401786 | Phase II | Cemiplimab Ipilimumab | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) | Recruiting | NLD | 0 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05430009 | Phase I | Pembrolizumab | Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05435846 | Phase I | Capmatinib + Trametinib | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Terminated | USA | 0 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT05443971 | Phase II | Durvalumab | Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen | Recruiting | USA | 0 |
NCT05445843 | Phase II | JDQ443 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation. | Active, not recruiting | USA | TUR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | BEL | AUT | ARG | 5 |
NCT05450562 | Phase Ib/II | Atezolizumab + SAR444200 SAR444200 | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 3 |
NCT05450692 | Phase III | Docetaxel Ceralasertib + Durvalumab | A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 7 |
NCT05462873 | Phase I | QEQ278 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT05467748 | Phase Ib/II | Tazemetostat | EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT05472623 | Phase II | Adagrasib + Nivolumab Adagrasib | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab (Neo-Kan) | Recruiting | USA | 0 |
NCT05483491 | Phase I | Aldesleukin + KK-LC-1 TCR-T cells | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Recruiting | USA | 0 |
NCT05487235 | Phase I | Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | POL | NZL | ESP | CAN | BRA | AUS | ARG | 2 |
NCT05488314 | Phase II | Amivantamab-vmjw + Capmatinib | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark) | Active, not recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | 3 |
NCT05493501 | Phase III | Aumolertinib + Cisplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Pemetrexed Disodium Aumolertinib + Carboplatin + Paclitaxel Aumolertinib + Cisplatin + Paclitaxel Aumolertinib + Cisplatin + Nab-paclitaxel Aumolertinib + Carboplatin + Nab-paclitaxel Aumolertinib + Cisplatin + Gemcitabine Aumolertinib Aumolertinib + Carboplatin + Gemcitabine Osimertinib | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | Terminated | USA | 0 |
NCT05493566 | Phase I | Aldesleukin + Pembrolizumab | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05498389 | Phase Ib/II | EMB-01 + Osimertinib | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | Not yet recruiting | USA | 1 |
NCT05498428 | Phase II | Amivantamab-vmjw Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | BRA | 4 |
NCT05500092 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (CA209-6K6) | Recruiting | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05501665 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | Recruiting | USA | 0 |
NCT05502237 | Phase III | AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) | Active, not recruiting | USA | TUR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | ARG | 9 |
NCT05514496 | Phase I | NX-019 | A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer | Recruiting | USA | 2 |
NCT05519293 | Phase Ib/II | H002 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Recruiting | USA | 0 |
NCT05525338 | FDA approved | Alectinib | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) | Recruiting | NLD | FRA | 0 |
NCT05526755 | Phase II | Osimertinib | A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET) | Active, not recruiting | USA | ITA | GBR | ESP | 7 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05537740 | Phase I | BAY 3375968 + Pembrolizumab BAY 3375968 | A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | BEL | 2 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05541822 | Phase II | ABN401 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Recruiting | USA | 2 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05546268 | Phase Ib/II | MRT-2359 | Study of Oral MRT-2359 in Selected Cancer Patients | Recruiting | USA | CAN | 0 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05548634 | Phase I | TAVO412 | A Study of TAVO412 in Patients With Cancer (TAVO412) | Active, not recruiting | USA | 0 |
NCT05553834 | Phase II | Alirocumab + Cemiplimab | PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | Recruiting | USA | 0 |
NCT05555732 | Phase III | Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT05565378 | Phase II | Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Recruiting | USA | TUR | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | BRA | BEL | ARG | 7 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05566223 | Phase Ib/II | Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine Pembrolizumab | Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2) | Not yet recruiting | USA | 0 |
NCT05568212 | Phase II | Durvalumab Durvalumab + Olaparib | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | Recruiting | ITA | 0 |
NCT05570825 | Phase II | Pembrolizumab + SX-682 | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | 0 |
NCT05573035 | Phase I | LYL845 | A Study to Investigate LYL845 in Adults With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Recruiting | USA | 1 |
NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 1 |
NCT05580770 | Phase Ib/II | BGB3245 + PD-0325901 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT05583188 | FDA approved | Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium | Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) | Terminated | USA | 0 |
NCT05584670 | Phase Ib/II | SAR445877 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | NLD | ISR | ESP | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05588609 | Phase II | Enzalutamide + Zenocutuzumab Afatinib + Zenocutuzumab Abiraterone + Zenocutuzumab | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Active, not recruiting | USA | 0 |
NCT05589818 | Phase II | Pembrolizumab | Pembrolizumab for Advanced NSCLC and PS 2-3 | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05597800 | Phase II | Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR) | Not yet recruiting | ITA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05598853 | Phase I | Ipilimumab + Nivolumab | Intrathecal Double Checkpoint Inhibition (IT-IO) | Recruiting | CHE | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05609578 | Phase II | Adagrasib + Pembrolizumab | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Recruiting | USA | POL | ITA | HUN | GRC | FRA | ESP | CHE | BRA | 5 |
NCT05609968 | Phase III | Pembrolizumab Pembrolizumab + Sacituzumab govitecan-hziy | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-3475-D46) | Recruiting | USA | TUR | ROU | POL | LVA | LTU | ITA | ISR | GRC | GBR | EST | DEU | CAN | BRA | AUS | 9 |
NCT05613413 | Phase II | Cabozantinib + Pembrolizumab | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127) | Recruiting | USA | 0 |
NCT05614102 | Phase I | BAY2965501 | A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | BEL | 3 |
NCT05617313 | Phase II | GT103 + Pembrolizumab | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620342 | Phase I | iC9.GD2.CAR.IL-15 T-cells | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Recruiting | USA | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05624996 | Phase III | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05627960 | Phase I | AG01 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05631249 | Phase II | Sotorasib | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK-IGR) | Recruiting | FRA | 0 |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 1 |
NCT05632809 | Phase II | Durvalumab + NKTR-255 | REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | Recruiting | USA | 0 |
NCT05633602 | Phase III | Pembrolizumab + Ramucirumab | Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | Recruiting | USA | 0 |
NCT05633667 | Phase II | Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Sacituzumab govitecan-hziy + Zimberelimab AB154 + Etrumadenant + Zimberelimab Sacituzumab govitecan-hziy | Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) | Recruiting | USA | ISR | GBR | BRA | 3 |
NCT05635708 | Phase II | Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Recruiting | USA | ROU | ITA | FRA | ESP | CAN | BRA | AUS | 7 |
NCT05642195 | Phase Ib/II | H1299 cell lysate vaccine + Montanide ISA 51 + Nogapendekin alfa inbakicept H1299 cell lysate vaccine + Montanide ISA 51 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | Suspended | USA | 0 |
NCT05642572 | Phase II | Capmatinib + Osimertinib Capmatinib + Osimertinib + Ramucirumab | Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05647122 | Phase I | AZD9592 AZD9592 + Osimertinib | First in Human Study of AZD9592 in Solid Tumors (EGRET) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05652868 | Phase I | MYTX-011 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | AUS | 2 |
NCT05653752 | Phase I | YL202 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | Recruiting | USA | 1 |
NCT05663866 | Phase II | Amivantamab-vmjw + Dexamethasone + Lazertinib Amivantamab-vmjw + Lazertinib + Montelukast Amivantamab-vmjw + Lazertinib + Methotrexate | Premedication to Mitigate Amivantamab Infusion Related Reactions | Active, not recruiting | USA | FRA | ESP | 2 |
NCT05668585 | Phase Ib/II | Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05669846 | Phase II | Fecal microbiota + Pembrolizumab | Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC | Not yet recruiting | USA | 0 |
NCT05671510 | Phase III | ONC-392 Docetaxel | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) | Recruiting | USA | TUR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05673187 | Phase II | Adagrasib | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT) | Recruiting | ITA | IRL | GBR | FRA | ESP | BEL | 0 |
NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05676931 | Phase II | AB680 + Zimberelimab AB154 + Zimberelimab AB154 + AB680 + Zimberelimab AB680 + Docetaxel + Zimberelimab AB154 + Docetaxel + Zimberelimab | Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | AUS | 3 |
NCT05681780 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Recruiting | USA | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05684276 | Phase II | Carboplatin + Nivolumab + Paclitaxel | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (DUMAS) | Recruiting | ESP | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05687266 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) | Recruiting | USA | TUR | SWE | POL | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BGR | AUT | 8 |
NCT05688280 | Phase Ib/II | IP-001 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) | Recruiting | USA | GBR | FRA | DEU | CHE | 0 |
NCT05691829 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung) | Active, not recruiting | USA | 0 |
NCT05696782 | Phase II | Durvalumab | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | Recruiting | USA | 0 |
NCT05700721 | Phase II | Dostarlimab-gxly + Niraparib | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | Recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05714891 | Phase II | JDQ443 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | Recruiting | CAN | 0 |
NCT05715229 | Phase II | Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT) | Recruiting | USA | 0 |
NCT05718297 | Phase II | Brigatinib Durvalumab | Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) | Withdrawn | POL | ITA | GBR | FRA | ESP | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05722015 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + MK-3475A + Nab-paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Cisplatin + MK-3475A + Pemetrexed Disodium Carboplatin + MK-3475A + Paclitaxel | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | Active, not recruiting | USA | TUR | ROU | POL | HUN | FRA | ESP | BRA | ARG | 7 |
NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |
NCT05742607 | Phase II | Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Paclitaxel | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Recruiting | USA | POL | HUN | GRC | FRA | 0 |
NCT05756153 | Phase Ib/II | Cetuximab + IBI351 | A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation | Recruiting | ITA | GRC | ESP | 0 |
NCT05757492 | Phase Ib/II | CHS-006 + Toripalimab-tpzi | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT05757843 | Phase II | Durvalumab | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | Withdrawn | 0 | |
NCT05765734 | Phase Ib/II | TAS3351 | A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 2 |
NCT05769075 | Phase I | TY-2136b | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | Recruiting | USA | 0 |
NCT05775289 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | DEU | BRA | BEL | AUS | 2 |
NCT05777603 | Phase I | Aztreonam + Pembrolizumab + Vancomycin | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05781308 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) | Active, not recruiting | FRA | 0 |
NCT05782361 | Phase I | Pembrolizumab + Tepotinib | POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT) | Recruiting | GBR | 0 |
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05785208 | FDA approved | Osimertinib | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2) | Recruiting | ITA | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05785767 | Phase II | Cemiplimab Cemiplimab + Fianlimab | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | ISR | CAN | AUS | 5 |
NCT05786924 | Phase I | BDTX-4933 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | Active, not recruiting | USA | 0 |
NCT05788926 | Phase I | TG6050 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Recruiting | FRA | 0 |
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT05789082 | Phase Ib/II | Divarasib + Pembrolizumab | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | GBR | ESP | CHE | CAN | BRA | BEL | AUS | ARG | 3 |
NCT05798663 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | Recruiting | USA | 0 |
NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT05801029 | Phase II | Amivantamab-vmjw + Osimertinib | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA) | Recruiting | USA | CAN | 6 |
NCT05807048 | Phase II | Daratumumab and hyaluronidase-fihj | Daratumumab in STK11 Mutated NSCLC | Recruiting | USA | 0 |
NCT05815173 | Phase I | Ladarixin + Sotorasib | Ladarixin With Sotorasib in Advanced NSCLC | Recruiting | USA | 0 |
NCT05815186 | Phase II | Ladarixin + Sotorasib | Ladarixin With Sotorasib in Advanced NSCLC - Phase II | Withdrawn | USA | 0 |
NCT05816252 | Phase II | Osimertinib + SKB264 Carboplatin + SKB264 Carboplatin + Pembrolizumab + SKB264 Pembrolizumab + SKB264 | A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | TUR | ROU | ESP | 3 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05825625 | Phase II | Atezolizumab + Tiragolumab | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | Recruiting | DEU | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05840510 | Phase Ib/II | Adagrasib + Nab-rapamycin | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | Active, not recruiting | USA | 0 |
NCT05840770 | Phase II | Cemiplimab | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05845671 | Phase Ib/II | Amivantamab-vmjw | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | Recruiting | USA | 0 |
NCT05846646 | Phase II | Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | Terminated | USA | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
NCT05853575 | Phase II | Adagrasib | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | HRV | GRC | FRA | ESP | BRA | 5 |
NCT05858164 | Phase I | BAY2862789 | A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | ESP | AUS | 3 |
NCT05859217 | Phase II | Atezolizumab + Cabozantinib | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1) | Not yet recruiting | USA | 0 |
NCT05860296 | Phase Ib/II | Pembrolizumab + SLC-391 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Recruiting | USA | CAN | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Active, not recruiting | ESP | AUT | 0 |
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT05877430 | Phase Ib/II | CJRB-101 + Pembrolizumab | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Recruiting | USA | 1 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05888831 | Phase Ib/II | BMS-986449 + Nivolumab BMS-986449 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | FRA | ESP | BEL | 0 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05898763 | Phase Ib/II | Pembrolizumab + TEIPP24 TEIPP24 | TEIPP Immunotherapy in Patients With NSCLC | Completed | NLD | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05908734 | Phase Ib/II | Amivantamab-vmjw + Cetrelimab | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) | Recruiting | USA | TUR | POL | ITA | GBR | ESP | BRA | 2 |
NCT05911308 | Phase I | Carboplatin + Durvalumab + Nab-paclitaxel + Pemetrexed Disodium + RGX-104 | Pilot Study of Abequolixron (RGX-104) and Durvalumab in Lung Cancer | Recruiting | USA | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05919537 | Phase Ib/II | Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | Recruiting | AUS | 0 |
NCT05920135 | Phase Ib/II | BBT-207 | First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI | Recruiting | USA | 1 |
NCT05920356 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Sotorasib | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Recruiting | USA | TUR | SWE | ROU | POL | NLD | LVA | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 12 |
NCT05920408 | Phase Ib/II | EXS21546 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | Terminated | FRA | BEL | 0 |
NCT05925530 | Phase II | Durvalumab | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) | Recruiting | USA | SWE | ITA | HUN | FRA | ESP | DEU | CZE | CAN | AUT | 1 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05935774 | Phase II | Atezolizumab + Trabedersen | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05948462 | Phase II | Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC) | Withdrawn | USA | 0 |
NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT05967689 | Phase II | Zipalertinib | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2) | Recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05975073 | Phase Ib/II | AMG193 + IDE397 | A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | Recruiting | USA | ESP | DNK | CAN | AUS | 2 |
NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05983432 | Phase I | BL-B01D1 | Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ESP | 0 |
NCT05984277 | Phase III | Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02) | Recruiting | USA | TUR | SVK | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT05987644 | Phase Ib/II | Alectinib | Delayed or Upfront Brain RAdiotherapy in Treatment naive Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE) | Recruiting | USA | 0 |
NCT06000358 | Pembrolizumab | The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer (LUCACRIMUNO) | Recruiting | LTU | 0 | |
NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06007937 | Phase Ib/II | Lorlatinib + Ramucirumab | A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | Recruiting | USA | 0 |
NCT06010329 | Phase II | Sutetinib maleate | A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Recruiting | USA | 0 |
NCT06014827 | Phase II | Osimertinib | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma | Recruiting | USA | 0 |
NCT06015724 | Phase II | Daratumumab + Nivolumab + QS21 + TG01 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX) | Recruiting | USA | 0 |
NCT06024174 | Phase Ib/II | Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | Terminated | USA | ISR | FRA | FIN | AUS | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06031688 | Phase II | Tepotinib Ramucirumab + Tepotinib | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06039384 | Phase I | Adagrasib + INCB099280 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Active, not recruiting | USA | ITA | GBR | ESP | 0 |
NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Recruiting | USA | 0 |
NCT06043817 | Phase Ib/II | STX-721 | First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations | Recruiting | USA | NLD | FRA | ESP | DEU | 1 |
NCT06046495 | Phase I | PLB1004 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06051695 | Phase Ib/II | A2B694 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) | Recruiting | USA | 0 |
NCT06052852 | Phase Ib/II | BDC-3042 + Pembrolizumab BDC-3042 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06060613 | Phase Ib/II | OBX-115 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06064279 | Phase Ib/II | Poly ICLC | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI) | Withdrawn | USA | 0 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
NCT06067776 | Phase I | Cetuximab + Osimertinib + Tucatinib | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | Not yet recruiting | USA | 0 |
NCT06068153 | Phase II | Lenvatinib + Sotorasib | AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC (AMBER) | Withdrawn | ESP | DEU | CHE | AUT | 0 |
NCT06069570 | Phase I | KB-GDT-01 | Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC | Recruiting | USA | 0 |
NCT06077760 | Phase III | mRNA-4157 + Pembrolizumab Pembrolizumab | A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Recruiting | USA | TUR | SVK | POL | NZL | NOR | LVA | LTU | ITA | IRL | HUN | GRC | FRA | FIN | EST | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 7 |
NCT06083454 | Phase I | Durvalumab Durvalumab + Vitamin C | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT06083857 | Phase Ib/II | Amivantamab-vmjw + Tepotinib | PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT06088771 | Phase Ib/II | Cemiplimab + Dupilumab | Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | Recruiting | USA | 0 |
NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Completed | USA | AUS | 0 |
NCT06096844 | Phase III | Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium | Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Recruiting | USA | 0 |
NCT06099639 | Expanded access | Patritumab deruxtecan | Medical Access Program for Patritumab Deruxtecan | Available | USA | 0 |
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Recruiting | USA | 0 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06116786 | Phase I | Cetrelimab + JNJ-86974680 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | 1 |
NCT06119581 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium | A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06120283 | Phase I | BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06124118 | Phase I | Durvalumab Carboplatin + Paclitaxel | Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE) | Recruiting | USA | 0 |
NCT06125197 | Phase I | Pembrolizumab + TILT-123 | Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06128551 | Phase I | RMC-6236 + RMC-6291 | Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | 1 |
NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Recruiting | USA | 0 |
NCT06131398 | Phase I | AMG 355 + Pembrolizumab AMG 355 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Recruiting | USA | POL | NLD | FRA | ESP | CHE | CAN | AUS | 3 |
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |
NCT06140836 | Phase III | Repotrectinib Crizotinib | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CHE | CAN | BRA | AUT | ARG | 6 |
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06161441 | Phase II | Carboplatin + Cemiplimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Paclitaxel Cemiplimab + Fianlimab Cemiplimab + Cisplatin + Paclitaxel Cemiplimab + Cisplatin + Pemetrexed Disodium Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Fianlimab + Paclitaxel | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | Recruiting | USA | AUS | 2 |
NCT06162221 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291 | Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | 0 |
NCT06162572 | Phase Ib/II | Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | ROU | ITA | HUN | GBR | FRA | ESP | BRA | BEL | AUT | AUS | ARG | 3 |
NCT06163391 | Phase I | SOT201 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | Recruiting | USA | FRA | ESP | CZE | BEL | 0 |
NCT06170788 | Phase III | Pembrolizumab + SKB264 Pembrolizumab | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) | Recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | ARG | 9 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06179160 | Phase I | Cetuximab + INCB161734 + Retifanlimab INCB161734 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT06188208 | Phase I | Pembrolizumab + VVD-130850 VVD-130850 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | Recruiting | USA | ESP | AUS | 0 |
NCT06194448 | Phase II | Carboplatin + Pemetrexed Disodium Osimertinib Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Pemetrexed Disodium | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA) | Recruiting | USA | TUR | ISR | ESP | 6 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06216301 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2) | Recruiting | USA | 0 |
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Recruiting | USA | 0 |
NCT06219174 | Phase Ib/II | Eflornithine + Pembrolizumab | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) | Recruiting | USA | 0 |
NCT06225427 | Phase I | Gilteritinib | Gilteritinib for the Treatment of ALK NSCLC | Recruiting | USA | 0 |
NCT06225804 | Phase I | ABSK112 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT06226766 | Phase Ib/II | JSKN033 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Recruiting | AUS | 0 |
NCT06228482 | Phase I | 177Lu-DOTA-ABM-5G | Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 | Recruiting | USA | 0 |
NCT06237881 | Phase Ib/II | Cyclophosphamide + Fludarabine KSQ-001EX Aldesleukin + KSQ-001EX | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06246110 | Phase II | Carboplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Paclitaxel + Pembrolizumab | A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06248606 | Phase II | Adagrasib | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | Recruiting | USA | 0 |
NCT06249282 | Phase I | Carfilzomib + Sotorasib | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT06267001 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15) | Active, not recruiting | USA | TUR | SVK | POL | ITA | FRA | ESP | BRA | AUS | ARG | 6 |
NCT06268613 | Phase I | Pembrolizumab | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | Recruiting | TUR | POL | ESP | 1 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06275360 | Phase II | Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) | Recruiting | USA | 0 |
NCT06285097 | Phase I | PF-07820435 PF-06801591 + PF-07820435 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 2 |
NCT06303505 | Phase Ib/II | TUB-040 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01) | Recruiting | USA | ESP | DEU | BEL | 1 |
NCT06305962 | Phase I | 177Lu-RAD204 | 177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer | Recruiting | AUS | 0 |
NCT06311578 | Phase I | JNJ-87704916 Cetrelimab + JNJ-87704916 | A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06331455 | Phase II | Durvalumab | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER) | Recruiting | CAN | 0 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT06332274 | Phase III | Tislelizumab | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) | Not yet recruiting | FRA | 0 |
NCT06332755 | Phase I | LB-LR1109 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) | Recruiting | USA | 0 |
NCT06333678 | Phase II | Durvalumab Sotorasib | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT06333951 | Phase I | AMG193 + Pembrolizumab AMG193 + Carboplatin + Pembrolizumab + Pemetrexed Disodium AMG193 AMG193 + Sotorasib AMG193 + Carboplatin + Paclitaxel + Pembrolizumab | AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Recruiting | USA | AUS | 3 |
NCT06343402 | Phase I | BBO-8520 BBO-8520 + Pembrolizumab | Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Recruiting | USA | AUS | 0 |
NCT06345729 | Phase III | Pembrolizumab MK-1084 + Pembrolizumab | A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-1084-004) | Recruiting | USA | NZL | BRA | AUS | ARG | 5 |
NCT06357533 | Phase III | Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 6 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Not yet recruiting | USA | 0 |
NCT06378892 | Phase II | Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium Lorlatinib + Pemetrexed Disodium | A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL) | Recruiting | ITA | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06385262 | Phase II | Cemiplimab Alirocumab + Cemiplimab | TOP 2301: Neoadjuvant Chemo for NSCLC | Recruiting | USA | 0 |
NCT06400472 | Phase I | LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT06405230 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Dostarlimab-gxly Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Pembrolizumab | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | Not yet recruiting | GBR | 0 |
NCT06431633 | Phase II | Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) | Not yet recruiting | ESP | 0 |
NCT06447662 | Phase I | PF-07934040 Gemcitabine + Nab-paclitaxel + PF-07934040 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 Pembrolizumab + PF-07934040 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07934040 Cetuximab + PF-07934040 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Recruiting | USA | 1 |
NCT06448364 | Phase I | PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) | Terminated | USA | 1 |
NCT06449313 | Phase II | Cemiplimab | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement (NEO-SURG) | Not yet recruiting | USA | 0 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06465329 | Phase II | Cemiplimab + REGN7075 REGN7075 Cemiplimab | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06470763 | Phase Ib/II | ANV600 ANV600 + Pembrolizumab | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06472076 | Phase III | Pembrolizumab Dostarlimab-gxly + EOS-448 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) | Recruiting | TUR | SWE | SVN | SVK | ROU | POL | NLD | ITA | HUN | HRV | GRC | FRA | FIN | EST | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 12 |
NCT06475937 | Phase I | DM001 | A Study of DM001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06480240 | Phase Ib/II | OBI-992 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06486142 | Phase III | Osimertinib Afatinib Dacomitinib | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study (ERIS) | Recruiting | SWE | 0 |
NCT06495125 | Phase II | Defactinib + Nivolumab + RO5126766 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06497556 | Phase III | Divarasib Sotorasib Adagrasib | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1) | Recruiting | USA | SWE | POL | ITA | GBR | FRA | DNK | DEU | BRA | AUS | ARG | 3 |
NCT06507306 | Phase I | KQB198 + Osimertinib KQB198 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06521554 | Phase I | NVL-330 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Recruiting | USA | 0 |
NCT06522360 | Phase II | Brigatinib Brigatinib + Carboplatin + Pemetrexed Disodium | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) | Not yet recruiting | USA | 0 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06532032 | Phase Ib/II | Amivantamab-vmjw + Docetaxel | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) | Recruiting | USA | TUR | 1 |
NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06545331 | Phase I | Pembrolizumab + XB010 XB010 | Study of XB010 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT06546553 | Phase I | PF-07826390 PF-06801591 + PF-07826390 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. | Recruiting | USA | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06552234 | Phase II | Repotrectinib | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC (REPOROS) | Not yet recruiting | FRA | 0 |
NCT06555263 | Phase II | Luveltamab Tazevibulin | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06558799 | Phase II | Pembrolizumab | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) (LUNAR-4) | Recruiting | AUT | 0 |
NCT06561685 | Phase I | LY4050784 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT06567015 | Phase Ib/II | STX-241 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs (STX-241 FIH) | Recruiting | USA | NLD | FRA | ESP | DEU | 2 |
NCT06577987 | Phase I | CID-078 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT06579196 | Phase Ib/II | Pembrolizumab + Trabedersen | Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 | Not yet recruiting | USA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06582771 | Phase II | Sotorasib | A Study of Sotorasib in People With Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06599502 | Phase Ib/II | AZD0022 + Cetuximab AZD0022 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Recruiting | USA | TUR | POL | NLD | ITA | ESP | CAN | BEL | AUS | 0 |
NCT06616623 | Phase I | Atezolizumab + Vismodegib | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | Not yet recruiting | USA | 0 |
NCT06623656 | Phase II | Cemiplimab | Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | Not yet recruiting | USA | 0 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06635824 | Phase III | Docetaxel GEN1046 + Pembrolizumab | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Recruiting | USA | 0 |
NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |
NCT06651593 | Phase II | BND-22 + Cemiplimab | Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | Not yet recruiting | USA | 0 |
NCT06667154 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | Recruiting | BRA | 0 |
NCT06667908 | Phase II | Carboplatin + JNJ-90301900 + Paclitaxel Carboplatin + Paclitaxel Durvalumab | A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (CONVERGE) | Not yet recruiting | USA | 0 |
NCT06669117 | Phase Ib/II | VERT-002 | FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations | Recruiting | USA | 0 |
NCT06680050 | Phase II | Ceralasertib + Durvalumab | Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL) | Not yet recruiting | ITA | CHE | 0 |